Members
 | First name: Diane Last name: Descamps Function: DeSCID Co-leader, researcher Position: Professor of Medicine, Université Paris Cité Email: diane.descampsaphp.fr |
Research interest
My research activities are focused since the past 30 years on HIV antiretroviral drug resistance and therapeutic strategies and viral diversity. It involves close collaboration between clinical virologists, infectious disease clinicians and clinical pharmacologists to combine task forces together, given our desire to continue our bio-clinical research on therapeutic aspects of HIV infection within a more general framework.
Education
Degree
2005: Habilitation to conduct researches, University Paris Diderot, Paris
1999: Ph. D. in Microbiology, University Pierre and Marie Curie, Paris
1993: M. D. Necker-Enfants Malades Medical School, Paris Descartes University, Paris
1988 : Residency of Paris-Ile de France
1987: Second cycle of Medical Studies, University Paris Descartes, Paris
1999: Ph. D. in Microbiology, University Pierre and Marie Curie, Paris
1993: M. D. Necker-Enfants Malades Medical School, Paris Descartes University, Paris
1988 : Residency of Paris-Ile de France
1987: Second cycle of Medical Studies, University Paris Descartes, Paris
Academic positions
2012-present: Head of the Virology Department, Bichat-Claude Bernard Hospital, Université Paris Cité, Paris
2009-present: Professor of Medicine, Medical School, Université Paris Cité, Paris
1999-2008: Associate Professor, Medical School, Paris-Diderot University, Paris
1993-1997: Assistant Professor, Medical School, Paris-Diderot
1987-1992: Resident, University Hospital of Paris, Paris
2009-present: Professor of Medicine, Medical School, Université Paris Cité, Paris
1999-2008: Associate Professor, Medical School, Paris-Diderot University, Paris
1993-1997: Assistant Professor, Medical School, Paris-Diderot
1987-1992: Resident, University Hospital of Paris, Paris
Research training (post doctoral)
2020-present: Co-leader of DeSCID team, IAME research unit, Paris
2014-2018: Leader of STAR team IAME, IAME research unit, Paris
2009-2014: Researcher at University Paris-Diderot Research Unit 4409, Bichat- Claude Bernard Hospital, Paris
2005-2006: Visiting Fellow, Department of Methodology and Biostatistics, INSERM U1136, University Pierre and Marie Curie (UPMC)
1998-2008: Researcher at INSERM research Unit 552, Bichat-Claude Bernard Hospital, Paris
2014-2018: Leader of STAR team IAME, IAME research unit, Paris
2009-2014: Researcher at University Paris-Diderot Research Unit 4409, Bichat- Claude Bernard Hospital, Paris
2005-2006: Visiting Fellow, Department of Methodology and Biostatistics, INSERM U1136, University Pierre and Marie Curie (UPMC)
1998-2008: Researcher at INSERM research Unit 552, Bichat-Claude Bernard Hospital, Paris
List of the main publications
Piorkowski G, Ghosn J, Coppée R, Mailhé M, Ferré VM, Houhou-Fidouh N, Yazdanpanah Y, Le Hingrat Q, Raoul H, Charpentier C, Descamps D, de Lamballerie X
Genomic diversity of mpox virus in Paris area (France) during the 2022 outbreak.
Journal of Medical Virology 2023, 95, e28853.
Mailhe M, Beaumont AL, Thy M, Le Pluart D, Perrineau S, Houhou-Fidouh N, Deconinck L, Bertin C, Ferré VM, Cortier M, De La Porte Des Vaux C, Phung BC, Mollo B, Cresta M, Bouscarat F, Choquet C, Descamps D, Ghosn J, Lescure FX, Yazdanpanah Y, Joly V, Peiffer-Smadja N
Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2023, 29, 233-239.
Schramm B, Temfack E, Descamps D, Nicholas S, Peytavin G, Bitilinyu-Bangoh JE, Storto A, Lê MP, Abdi B, Ousley J, Kalua T, Calvez V, Jahn A, Marcelin AG, Szumilin E
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
The lancet. HIV 2022, 9, e544-e553.
Le Hingrat Q, Collin G, Damond F, Peytavin G, Lebourgeois S, Ghosn J, Bachelard A, Ferré VM, Matheron S, Descamps D, Charpentier C
In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions.
The Journal of Antimicrobial Chemotherapy 2022, 77, 409-412.
Le Hingrat Q, Collin G, Bachelard A, Ghosn J, Chalal S, Pacanowski J, Peytavin G, Weinheimer S, Marsolais C, Damond F, Matheron S, Charpentier C, Descamps D, and the ANRS CO5 HIV-2 cohort
Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates.
AIDS (London, England) 2022
Ferré VM, Bachelard A, Zaidi M, Armand-Lefevre L, Descamps D, Charpentier C, Ghosn J
Detection of Monkeypox Virus in Anorectal Swabs From Asymptomatic Men Who Have Sex With Men in a Sexually Transmitted Infection Screening Program in Paris, France.
Annals of Internal Medicine 2022, 175, 1491-1492.
Visseaux B, Bertine M, Le Hingrat Q, Ferré V, Charpentier C, Collin F, Damond F, Matheron S, Hué S, Descamps D
HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution.
Virus Evolution 2021, 7, veab024.
Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A, Bouscambert-Duchamp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y
Clinical and virological data of the first cases of COVID-19 in Europe: a case series.
The Lancet. Infectious Diseases 2020, 20, 697-706.
Le Hingrat Q, Visseaux B, Bertine M, Chauveau L, Schwartz O, Collin F, Damond F, Matheron S, Descamps D, Charpentier C
Genetic Variability of Long Terminal Repeat Region between HIV-2 Groups Impacts Transcriptional Activity.
Journal of Virology 2020, 94,
Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y, LAMIDOL Study Group
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
The Journal of Antimicrobial Chemotherapy 2019, 74, 739-745.
Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D, AA4RSG
Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1417-1424.
Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D, ANRS AC-43 Resistance Study Group
Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1417-1424.
Storto A, Visseaux B, Bertine M, Le Hingrat Q, Collin G, Damond F, Khuong MA, Blum L, Tubiana R, Karmochkine M, Cazanave C, Matheron S, Descamps D, Charpentier C, ANRS HIV-2 CO5 Cohort
Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2018
Perrier M, Charpentier C, Peytavin G, Lê M, Blondel L, Visseaux B, Joly V, Pinto A, Matheron S, Yazdanpanah Y, Descamps D, Landman R
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1745-1751.
Bertine M, Visseaux B, Storto A, Collin G, Matheron S, Descamps D, Charpentier C, ANRS CO5 HIV-2 Cohort
HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
Journal of Acquired Immune Deficiency Syndromes (1999) 2016, 72, e9–e11.
Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, Charpentier C, Khuong-Josses MA, Duvivier C, Karmochkine M, Lukiana T, Matheron S
Dolutegravir in HIV-2 infected patients with resistant virus to first-line integrase inhibitors from the French Named Patient Program.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2015
Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.
Visseaux B, Charpentier C, Ozanne A, Nizard A, Drumard S, Fagard C, Glohi D, Damond F, Brun-Vézinet F, Matheron S, Descamps D, ANRS CO5 HIV-2 Cohort
Tropism distribution among antiretroviral-naive HIV-2-infected patients.
AIDS (London, England) 2015, 29, 2209–2212.
Deuzing IP, Charpentier C, Wright DW, Matheron S, Paton J, Frentz D, van de Vijver DA, Coveney PV, Descamps D, ANRS CO5 HIV-2 Cohort, Boucher CAB, Beerens N
Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.
J. Virol. 2015, 89, 833–843.
Avettand-Fenoel V, Damond F, Gueudin M, Matheron S, Mélard A, Collin G, Descamps D, Chaix ML, Rouzioux C, Plantier JC, ANRS-CO5 HIV-2 and the ANRS-AC11 Quantification Working Group
New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load.
Journal of Clinical Microbiology 2014, 52, 3017–3022.
Larrouy L, Vivot A, Charpentier C, Bénard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D, ANRS CO5 HIV-2 Cohort
Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
AIDS (London, England) 2013, 27, 69-80.
Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort
Transmitted drug resistance in French HIV-2-infected patients.
AIDS 2013, 27, 1671–1674.
Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, ANRS CO 05 HIV-2 Cohort
Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
The Journal of Infectious Diseases 2012, 205, 111-120.
Genomic diversity of mpox virus in Paris area (France) during the 2022 outbreak.
Journal of Medical Virology 2023, 95, e28853.
Mailhe M, Beaumont AL, Thy M, Le Pluart D, Perrineau S, Houhou-Fidouh N, Deconinck L, Bertin C, Ferré VM, Cortier M, De La Porte Des Vaux C, Phung BC, Mollo B, Cresta M, Bouscarat F, Choquet C, Descamps D, Ghosn J, Lescure FX, Yazdanpanah Y, Joly V, Peiffer-Smadja N
Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2023, 29, 233-239.
Schramm B, Temfack E, Descamps D, Nicholas S, Peytavin G, Bitilinyu-Bangoh JE, Storto A, Lê MP, Abdi B, Ousley J, Kalua T, Calvez V, Jahn A, Marcelin AG, Szumilin E
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
The lancet. HIV 2022, 9, e544-e553.
Le Hingrat Q, Collin G, Damond F, Peytavin G, Lebourgeois S, Ghosn J, Bachelard A, Ferré VM, Matheron S, Descamps D, Charpentier C
In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions.
The Journal of Antimicrobial Chemotherapy 2022, 77, 409-412.
Le Hingrat Q, Collin G, Bachelard A, Ghosn J, Chalal S, Pacanowski J, Peytavin G, Weinheimer S, Marsolais C, Damond F, Matheron S, Charpentier C, Descamps D, and the ANRS CO5 HIV-2 cohort
Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates.
AIDS (London, England) 2022
Ferré VM, Bachelard A, Zaidi M, Armand-Lefevre L, Descamps D, Charpentier C, Ghosn J
Detection of Monkeypox Virus in Anorectal Swabs From Asymptomatic Men Who Have Sex With Men in a Sexually Transmitted Infection Screening Program in Paris, France.
Annals of Internal Medicine 2022, 175, 1491-1492.
Visseaux B, Bertine M, Le Hingrat Q, Ferré V, Charpentier C, Collin F, Damond F, Matheron S, Hué S, Descamps D
HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution.
Virus Evolution 2021, 7, veab024.
Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A, Bouscambert-Duchamp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y
Clinical and virological data of the first cases of COVID-19 in Europe: a case series.
The Lancet. Infectious Diseases 2020, 20, 697-706.
Le Hingrat Q, Visseaux B, Bertine M, Chauveau L, Schwartz O, Collin F, Damond F, Matheron S, Descamps D, Charpentier C
Genetic Variability of Long Terminal Repeat Region between HIV-2 Groups Impacts Transcriptional Activity.
Journal of Virology 2020, 94,
Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y, LAMIDOL Study Group
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
The Journal of Antimicrobial Chemotherapy 2019, 74, 739-745.
Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D, AA4RSG
Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1417-1424.
Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D, ANRS AC-43 Resistance Study Group
Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1417-1424.
Storto A, Visseaux B, Bertine M, Le Hingrat Q, Collin G, Damond F, Khuong MA, Blum L, Tubiana R, Karmochkine M, Cazanave C, Matheron S, Descamps D, Charpentier C, ANRS HIV-2 CO5 Cohort
Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2018
Perrier M, Charpentier C, Peytavin G, Lê M, Blondel L, Visseaux B, Joly V, Pinto A, Matheron S, Yazdanpanah Y, Descamps D, Landman R
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1745-1751.
Bertine M, Visseaux B, Storto A, Collin G, Matheron S, Descamps D, Charpentier C, ANRS CO5 HIV-2 Cohort
HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
Journal of Acquired Immune Deficiency Syndromes (1999) 2016, 72, e9–e11.
Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, Charpentier C, Khuong-Josses MA, Duvivier C, Karmochkine M, Lukiana T, Matheron S
Dolutegravir in HIV-2 infected patients with resistant virus to first-line integrase inhibitors from the French Named Patient Program.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2015
Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.
Visseaux B, Charpentier C, Ozanne A, Nizard A, Drumard S, Fagard C, Glohi D, Damond F, Brun-Vézinet F, Matheron S, Descamps D, ANRS CO5 HIV-2 Cohort
Tropism distribution among antiretroviral-naive HIV-2-infected patients.
AIDS (London, England) 2015, 29, 2209–2212.
Deuzing IP, Charpentier C, Wright DW, Matheron S, Paton J, Frentz D, van de Vijver DA, Coveney PV, Descamps D, ANRS CO5 HIV-2 Cohort, Boucher CAB, Beerens N
Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.
J. Virol. 2015, 89, 833–843.
Avettand-Fenoel V, Damond F, Gueudin M, Matheron S, Mélard A, Collin G, Descamps D, Chaix ML, Rouzioux C, Plantier JC, ANRS-CO5 HIV-2 and the ANRS-AC11 Quantification Working Group
New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load.
Journal of Clinical Microbiology 2014, 52, 3017–3022.
Larrouy L, Vivot A, Charpentier C, Bénard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D, ANRS CO5 HIV-2 Cohort
Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
AIDS (London, England) 2013, 27, 69-80.
Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort
Transmitted drug resistance in French HIV-2-infected patients.
AIDS 2013, 27, 1671–1674.
Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, ANRS CO 05 HIV-2 Cohort
Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
The Journal of Infectious Diseases 2012, 205, 111-120.
Exhaustive list of publications
2024
Mokrani D, Le Hingrat Q, Thy M, Choquet C, Joly V, Lariven S, Rioux C, Deconinck L, Loubet P, Papo T, Crestani B, Bunel V, Bouadma L, Khalil A, Armand-Lefèvre L, Raynaud-Simon A, Timsit JF, Lescure FX, Yazdanpanah Y, Descamps D, Peiffer-Smadja N
Clinical characteristics and outcomes of respiratory syncytial virus-associated ARF in immunocompetent patients: A seven-year experience at a tertiary hospital in France.
The Journal of Infection 2024, 89, 106180.
Dosbaa A, Guilbaud R, Yusti AMF, Ferré VM, Charpentier C, Descamps D, Le Hingrat Q, Coppée R
RSV-GenoScan: An automated pipeline for whole-genome human respiratory syncytial virus (RSV) sequence analysis.
Journal of Virological Methods 2024, 327, 114938.
Wurtzer S, Guilbaud R, Levert M, Fagour N, Le Hingrat Q, Descamps D, Tarantola A, Grellet S, Londinsky N, Moskovoy JM, Mouchel JM, Charpentier C, Moulin L
BA.2.86 variant emergence and spread dynamics through wastewater monitoring in Paris, France.
The Science of the Total Environment 2024, 917, 170355.
Bachelard A, Le Hingrat Q, Ferré VM, Lê M, Peytavin G, Damond F, Charpentier C, Fremont Goudot G, Goupil de Bouille J, Lariven S, Delobel P, Yazdanpanah Y, Descamps D, Matheron S, Ghosn J, ANRS CO05 VIH-2 cohort study group
Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2024, 78, 1005-1010.
Konu YR, Takassi E, Peytavin G, Dapam N, Damond F, Oumarou WA, Zaidi M, Franco-Yusti AM, Dagnra CA, Le Hingrat Q, Coppée R, Descamps D, Diallo FBT, Ekouevi DK, Charpentier C
Pharmaco-virological outcomes and genotypic resistance profiles among children and adolescents receiving a DTG-based regimen in Togo.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2024, ciae278.
Guilbaud R, Franco Yusti AM, Leducq V, Zafilaza K, Bridier-Nahmias A, Todesco E, Soulie C, Fauchois A, Le Hingrat Q, Kramer L, Goulenok T, Salpin M, Daugas E, Dorent R, Ottaviani S, Zalcman G, Ghosn J, Choquet S, Cacoub P, Amoura Z, Barroux B, Pourcher V, Spano JP, Louet M, Marcelin AG, Calvez V, Charpentier C, Descamps D, Marot S, Ferré VM, Coppée R
Higher Levels of SARS-CoV-2 Genetic Variation in Immunocompromised Patients: A Retrospective Case-Control Study.
The Journal of Infectious Diseases 2024, 229, 1041-1049.
Aghokeng AF, Ngo-Giang-Huong N, Huynh THK, Dagnra AY, D'Aquin Toni T, Maiga AI, Dramane K, Eymard-Duvernay S, Chaix ML, Calvez V, Descamps D, ANRS12425 Study Group
Prevalence of pretreatment HIV resistance to integrase inhibitors in West African and Southeast Asian countries.
The Journal of Antimicrobial Chemotherapy 2024, 79, 1164-1168.
Gracias S, El Yaalaoui I, Visseaux B, Charpentier C, Descamps D, Martin C, Lermechain F, Plantier JC, Alessandri-Gradt E
In vitro phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study.
Microbiology Spectrum 2024, 12, e0389523.
Sadio AJ, Ferré VM, Adama OIW, Kouanfack HR, Dagnra AC, Amenyah-Ehlan AP, Lawson-Ananissoh LM, Descamps D, Charpentier C, Ekouevi DK
Street adolescents in low income setting exposed to hepatitis B and C, and disadvantaged by lifestyle: a Togolese cross-sectional study.
BMC public health 2024, 24, 1901.
Bay P, Audureau E, Préau S, Favory R, Guigon A, Heming N, Gault E, Pham T, Chaghouri A, Turpin M, Morand-Joubert L, Jochmans S, Pitsch A, Meireles S, Contou D, Henry A, Joseph A, Chaix ML, Uhel F, Roux D, Descamps D, Emery M, Garcia-Sanchez C, Levy D, Burrel S, Mayaux J, Kimmoun A, Hartard C, Pène F, Rozenberg F, Gaudry S, Brichler S, Guillon A, Handala L, Tamion F, Moisan A, Daix T, Hantz S, Delamaire F, Thibault V, Souweine B, Henquell C, Picard L, Botterel F, Rodriguez C, Dessap AM, Pawlotsky JM, Fourati S, de Prost N, SEVARVIR investigators
COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variants.
Annals of Intensive Care 2024, 14, 65.
2023
Ferré VM, Bitty-Anderson AM, Peytavin G, Lê MP, Dagnra CA, Coppée R, Gbeasor-Komlanvi FA, Descamps D, Charpentier C, Ekouevi DK
Pharmaco-virological algorithm to target risk of drug resistance among a population of HIV-infected key populations in Togo.
Journal of Medical Virology 2023, 95, e28535.
Piorkowski G, Ghosn J, Coppée R, Mailhé M, Ferré VM, Houhou-Fidouh N, Yazdanpanah Y, Le Hingrat Q, Raoul H, Charpentier C, Descamps D, de Lamballerie X
Genomic diversity of mpox virus in Paris area (France) during the 2022 outbreak.
Journal of Medical Virology 2023, 95, e28853.
Chenane HR, Lingas G, Menidjel R, Laouenan C, Tubiana S, Descamps D, Le Hingrat Q, Abel L, Guedj J, Malhotra S, Kumar-Singh S, Visseaux B, Ghosn J, Charpentier C, Lebourgeois S, French COVID Cohort Study Group
High sera levels of SARS-CoV-2 N antigen are associated with death in hospitalized COVID-19 patients.
Journal of Medical Virology 2023, 95, e29247.
Mailhe M, Beaumont AL, Thy M, Le Pluart D, Perrineau S, Houhou-Fidouh N, Deconinck L, Bertin C, Ferré VM, Cortier M, De La Porte Des Vaux C, Phung BC, Mollo B, Cresta M, Bouscarat F, Choquet C, Descamps D, Ghosn J, Lescure FX, Yazdanpanah Y, Joly V, Peiffer-Smadja N
Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2023, 29, 233-239.
Bouzid D, Hingrat QL, Salipante F, Ferré VM, Chevallier T, Tubiana S, Lucet JC, Choquet C, Yazdanpanah Y, Timsit JF, Descamps D, Houhou N, Visseaux B, Loubet P
Agreement of respiratory viruses' detection between nasopharyngeal swab and bronchoalveolar lavage in adults admitted for pneumonia: a retrospective study.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2023, 29, 942.e1-942.e6.
Mageau A, Tchen J, Ferré VM, Nicaise-Roland P, Descamps D, Delory N, François C, Mendes C, Papo T, Goulenok T, Charles N, Sacré K
Impact of BNT162b2 mRNA anti-SARS-CoV-2 vaccine on interferon-alpha production by plasmacytoid dendritic cells and autoreactive T cells in patients with systemic lupus erythematosus: The COVALUS project.
Journal of Autoimmunity 2023, 134, 102987.
Farfour E, Lebourgeois S, Chenane HR, Charpentier C, Pascreau T, Jolly E, Descamps D, Vasse M, Visseaux B
SARS-CoV-2 viability and viral RNA persistence on microbiological agar plates.
The Journal of Hospital Infection 2023, 132, 140-142.
Coppée R, Chenane HR, Bridier-Nahmias A, Tcherakian C, Catherinot E, Collin G, Lebourgeois S, Visseaux B, Descamps D, Vasse M, Farfour E
Temporal dynamics of RSV shedding and genetic diversity in adults during the COVID-19 pandemic in a French hospital, early 2021.
Virus Research 2023, 323, 198950.
Bachelard A, Isernia V, Charpentier C, Benalycherif A, Mora M, Donadille C, Duvivier C, Lacombe K, El Mouhebb M, Spire B, Landman R, Descamps D, Peytavin G, Assoumou L, Ghosn J, FAST study group
Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055.
The Journal of Antimicrobial Chemotherapy 2023, 78, 769-778.
Armenia D, Santoro MM, Charpentier C, Bertoli A, Forbici F, Calvez V, Descamps D, Ceccherini-Silberstein F, Marcelin AG, Flandre P
Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.
The Journal of Antimicrobial Chemotherapy 2023, 78, 1415-1422.
Mazouz F, Bertine M, Coppée R, Storto A, Katlama C, Landman R, Cabié A, Peytavin G, Raffi F, Yazdanpanah Y, Descamps D, Joly V, Ghosn J, Charpentier C, LAMIDOL Study Group
Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir + lamivudine simplification in the ANRS 167 LAMIDOL trial.
The Journal of Antimicrobial Chemotherapy 2023, 78, 2995-3002.
Antoine M, Rubenstein E, Lascoux-Combe C, Chawki S, Zeggagh J, Pintado C, Tateo M, Ponscarme D, Ferre VM, Descamps D, Molina JM
Clinical Description of Sixty-Six Cases of Monkeypox Virus (MKPV) Infection Among Men Who Have Sex With Men (MSM) in an HIV/PrEP French Clinic.
Journal of Acquired Immune Deficiency Syndromes (1999) 2023, 92, e11-e14.
Sadio AJ, Ferré VM, Konu RY, Dagnra AC, Descamps D, Ekouevi DK, Charpentier C
High SARS-CoV-2 seroprevalence among street adolescents in Lomé, Togo, 2021.
BMC infectious diseases 2023, 23, 200.
de Prost N, Audureau E, Préau S, Favory R, Guigon A, Bay P, Heming N, Gault E, Pham T, Chaghouri A, Voiriot G, Morand-Joubert L, Jochmans S, Pitsch A, Meireles S, Contou D, Henry A, Joseph A, Chaix ML, Uhel F, Descamps D, Emery M, Garcia-Sanchez C, Luyt CE, Marot S, Pène F, Lhonneur AS, Gaudry S, Brichler S, Picard L, Mekontso Dessap A, Rodriguez C, Pawlotsky JM, Fourati S, SEVARVIR investigators
Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study.
Intensive Care Medicine Experimental 2023, 11, 48.
Inzaule SC, Siedner MJ, Little SJ, Avila-Rios S, Ayitewala A, Bosch RJ, Calvez V, Ceccherini-Silberstein F, Charpentier C, Descamps D, Eshleman SH, Fokam J, Frenkel LM, Gupta RK, Ioannidis JPA, Kaleebu P, Kantor R, Kassaye SG, Kosakovsky Pond SL, Kouamou V, Kouyos RD, Kuritzkes DR, Lessells R, Marcelin AG, Mbuagbaw L, Minalga B, Ndembi N, Neher RA, Paredes R, Pillay D, Raizes EG, Rhee SY, Richman DD, Ruxrungtham K, Sabeti PC, Schapiro JM, Sirivichayakul S, Steegen K, Sugiura W, van Zyl GU, Vandamme AM, Wensing AMJ, Wertheim JO, Gunthard HF, Jordan MR, Shafer RW
Recommendations on data sharing in HIV drug resistance research.
PLoS medicine 2023, 20, e1004293.
Tchounga BK, Bertine M, Damond F, Ferré VM, Inwoley A, Boni SP, Moisan A, Plantier JC, Descamps D, Ekouevi DK, Charpentier C
Molecular confirmation of HIV-1 and HIV-2 coinfections among initially serologically dually-reactive samples from patients living in West Africa.
PloS One 2023, 18, e0283602.
Kali S, Bourner J, Calmy A, Laouénan C, Merson L, Cervantes-Gonzalez M, Rojek A, Pesonel E, Guiraud L, Tardivon C, Descamps D, Diallo A, Gibowski S, Rosenthal E, Petrov-Sanchez V, Letrou S, Hoffmann I, Le Mestre S, Mentré F, Yazdanpanah Y, Olliaro P, Lescure FX
[MOSAIC: a European cohort study of human Mpox - the challenges of clinical research in outbreaks].
Virologie (Montrouge, France) 2023, 27, 23-26.
Kali S, Bourner J, Calmy A, Laouénan C, Merson L, Cervantes-Gonzalez M, Rojek A, Pesonel E, Guiraud L, Tardivon C, Descamps D, Diallo A, Gibowski S, Rosenthal E, Petrov-Sanchez V, Letrou S, Hoffmann I, Le Mestre S, Mentré F, Yazdanpanah Y, Olliaro P, Lescure FX
MOSAIC: a European cohort study of human Mpox - the challenges of clinical research in outbreaks.
Virologie (Montrouge, France) 2023, 27, 12-15.
Rezzoug I, Visseaux B, Bertine M, Parisey M, Bonnal C, Ruppe E, Descamps D, Timsit JF, Yazdanpanah Y, Armand-Lefevre L, Houze S, Argy N
Faecal Viral Excretion and Gastrointestinal Co-Infection Do Not Explain Digestive Presentation in COVID-19 Patients.
Microorganisms 2023, 11, 1780.
Charpentier C, Le Hingrat Q, Ferré VM, Damond F, Descamps D
Future of Antiretroviral Drugs and Evolution of HIV-1 Drug Resistance.
Viruses 2023, 15, 540.
Coppée R, Blanquart F, Jary A, Leducq V, Ferré VM, Franco Yusti AM, Daniel L, Charpentier C, Lebourgeois S, Zafilaza K, Calvez V, Descamps D, Marcelin AG, Visseaux B, Bridier-Nahmias A
Phylodynamics of SARS-CoV-2 in France, Europe, and the world in 2020.
eLife 2023, 12, e82538.
2022
Ayrolles A, Ellul P, Trebossen V, Houhou-Fidouh N, Bonacorsi S, Descamps D, Delorme R
Is SARS-CoV-2 seroconversion a risk factor for severe and acute psychiatric symptoms in children?.
Neuropsychopharmacology Reports 2022, 42, 218-220.
Ferré VM, Peiffer-Smadja N, Visseaux B, Descamps D, Ghosn J, Charpentier C
Omicron SARS-CoV-2 variant: What we know and what we don't.
Anaesthesia, Critical Care & Pain Medicine 2022, 41, 100998.
Barrière J, Carles M, Audigier-Valette C, Re D, Adjtoutah Z, Seitz-Polski B, Gounant V, Descamps D, Zalcman G
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article.
European Journal of Cancer (Oxford, England: 1990) 2022, 162, 182-193.
Bouzid D, Hadad O, Bertine M, Houhou-Fidouh N, Mirand A, Duval X, Bunel V, Borie R, Lucet JC, Descamps D, Visseaux B
Rhinoviruses: molecular diversity and clinical characteristics.
International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2022, 118, 144-149.
Santoro MM, Armenia D, Teyssou E, Santos JR, Charpentier C, Lambert-Niclot S, Antinori A, Katlama C, Descamps D, Perno CF, Calvez V, Paredes R, Ceccherini-Silberstein F, Marcelin AG, LAMRES Study Group
Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study.
Journal of Global Antimicrobial Resistance 2022, 31, 52-62.
Ferré VM, Lebourgeois S, Menidjel R, Collin G, Chenane HR, Guindi MO, Yazdanpanah Y, Timsit JF, Charpentier C, Descamps D, Fidouh N, Visseaux B
Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine.
The Journal of Infection 2022, 84, 248-288.
Lebourgeois S, Menidjel R, Chenane HR, Ferré VM, Collin G, Damond F, Coppée R, Yazdanpanah Y, Timsit JF, Houhou-Fidouh N, Descamps D, Charpentier C, Visseaux B
Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.
The Journal of Infection 2022, 84, 418-467.
Ferré VM, Lebourgeois S, Chenane HR, Menidjel R, Masson C, Collin G, Visseaux B, Descamps D, Fidouh N, Charpentier C
Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays.
The Journal of Infection 2022, S0163-4453(22)00126-8.
Gounant V, Ferré VM, Soussi G, Charpentier C, Flament H, Fidouh N, Collin G, Namour C, Assoun S, Bizot A, Brouk Z, Vicaut E, Teixeira L, Descamps D, Zalcman G
Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.
Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2022, 17, 239-251.
Schramm B, Temfack E, Descamps D, Nicholas S, Peytavin G, Bitilinyu-Bangoh JE, Storto A, Lê MP, Abdi B, Ousley J, Kalua T, Calvez V, Jahn A, Marcelin AG, Szumilin E
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
The lancet. HIV 2022, 9, e544-e553.
Goulenok T, Delaval L, Delory N, François C, Papo T, Descamps D, Ferré VM, Sacré K
Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases.
The Lancet. Rheumatology 2022, 4, e458-e461.
de Prost N, Audureau E, Heming N, Gault E, Pham T, Chaghouri A, de Montmollin N, Voiriot G, Morand-Joubert L, Joseph A, Chaix ML, Préau S, Favory R, Guigon A, Luyt CE, Burrel S, Mayaux J, Marot S, Roux D, Descamps D, Meireles S, Pène F, Rozenberg F, Contou D, Henry A, Gaudry S, Brichler S, Timsit JF, Kimmoun A, Hartard C, Jandeaux LM, Fafi-Kremer S, Gabarre P, Emery M, Garcia-Sanchez C, Jochmans S, Pitsch A, Annane D, Azoulay E, Mekontso Dessap A, Rodriguez C, Pawlotsky JM, Fourati S
Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19.
Nature Communications 2022, 13, 6025.
Leducq V, Jary A, Bridier-Nahmias A, Daniel L, Zafilaza K, Damond F, Goldstein V, Duval A, Blanquart F, Calvez V, Descamps D, Marcelin AG, Visseaux B
Nosocomial transmission clusters and lineage diversity characterized by SARS-CoV-2 genomes from two large hospitals in Paris, France, in 2020.
Scientific Reports 2022, 12, 1094.
Le Hingrat Q, Collin G, Damond F, Peytavin G, Lebourgeois S, Ghosn J, Bachelard A, Ferré VM, Matheron S, Descamps D, Charpentier C
In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions.
The Journal of Antimicrobial Chemotherapy 2022, 77, 409-412.
Lê MP, Ferré VM, Mazy F, Bourgeois-Moine A, Damond F, Matheron S, Descamps D, Ghosn J, Peytavin G
Bictegravir pharmacokinetics in a late-presenting HIV-1-infected pregnant woman: a case report.
The Journal of Antimicrobial Chemotherapy 2022, 77, 851-853.
Le Pluart D, Ruyer-Thompson M, Ferré VM, Mailhe M, Descamps D, Bouscarat F, Lescure FX, Lucet JC, Yazdanpanah Y, Ghosn J
A Healthcare-Associated Infection With Monkeypox Virus of a Healthcare Worker During the 2022 Outbreak.
Open Forum Infectious Diseases 2022, 9, ofac520.
Le Hingrat Q, Collin G, Bachelard A, Ghosn J, Chalal S, Pacanowski J, Peytavin G, Weinheimer S, Marsolais C, Damond F, Matheron S, Charpentier C, Descamps D, and the ANRS CO5 HIV-2 cohort
Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates.
AIDS (London, England) 2022
Lapaillerie D, Charlier C, Guyonnet-Dupérat V, Murigneux E, Fernandes HS, Martins FG, Magalhães RP, Vieira TF, Richetta C, Subra F, Lebourgeois S, Charpentier C, Descamps D, Visseaux B, Weigel P, Favereaux A, Beauvineau C, Buron F, Teulade-Fichou MP, Routier S, Gallois-Montbrun S, Meertens L, Delelis O, Sousa SF, Parissi V
Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.
Antimicrobial Agents and Chemotherapy 2022, 66, e0008322.
Richetta C, Subra F, Malet I, Leh H, Charpentier C, Corona A, Collin G, Descamps D, Deprez E, Parissi V, Calvez V, Tramontano E, Marcelin AG, Delelis O
Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration.
Journal of Virology 2022, 96, e0067622.
Ferré VM, Peiffer-Smadja N, Kramer L, Coppée R, Kante A, Debarge M, Choquet C, Saint Joannis T, Bouzid D, Messika J, Le Grand J, Thy M, Kernéis S, Descamps D, Visseaux B, Ghosn J
Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy.
Microbiology Spectrum 2022, 10, e0215222.
Mageau A, Ferré VM, Goulenok T, Charpentier C, Delory N, Francois C, Houhou-Fidouh N, Papo T, Descamps D, Sacre K
Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 vaccine in patients with systemic lupus erythematosus (SLE).
Annals of the Rheumatic Diseases 2022, 81, 1194-1196.
Martin-Blondel G, Lescure FX, Assoumou L, Charpentier C, Chapplain JM, Perpoint T, Grouteau G, Cordel H, Pialoux G, Pacanowski J, Thy M, Bauvois A, Laureillard D, Hamrouni F, Algarte-Genin M, Poissy J, Descamps D, Costagliola D, CoCliCo Study Group
Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study.
BMC infectious diseases 2022, 22, 540.
Lebourgeois S, David A, Chenane HR, Granger V, Menidjel R, Fidouh N, Noël B, Delelis O, Richetta C, Charpentier C, Chollet-Martin S, Descamps D, Visseaux B, de Chaisemartin L
Differential activation of human neutrophils by SARS-CoV-2 variants of concern.
Frontiers in Immunology 2022, 13, 1010140.
Fourati S, Audureau E, Arrestier R, Marot S, Dubois C, Voiriot G, Luyt CE, Urbina T, Mayaux J, Roque-Afonso AM, Pham T, Landraud L, Visseaux B, Roux D, Bellaiche R, L'honneur AS, Ait Hamou Z, Brichler S, Gaudry S, Salmona M, Clere-Jehl R, Azoulay E, Morand-Joubert L, Marcelin AG, Chaix ML, Descamps D, Mekontso Dessap A, Rodriguez C, Pawlotsky JM, de Prost N
SARS-CoV-2 Genomic Characteristics and Clinical Impact of SARS-CoV-2 Viral Diversity in Critically Ill COVID-19 Patients: A Prospective Multicenter Cohort Study.
Viruses 2022, 14, 1529.
Ferré VM, Bachelard A, Zaidi M, Armand-Lefevre L, Descamps D, Charpentier C, Ghosn J
Detection of Monkeypox Virus in Anorectal Swabs From Asymptomatic Men Who Have Sex With Men in a Sexually Transmitted Infection Screening Program in Paris, France.
Annals of Internal Medicine 2022, 175, 1491-1492.
2021
Vauloup-Fellous C, Maylin S, Périllaud-Dubois C, Brichler S, Alloui C, Gordien E, Rameix-Welti MA, Gault E, Moreau F, Fourati S, Challine D, Pawlotsky JM, Houhou-Fidouh N, Damond F, Mackiewicz V, Charpentier C, Méritet JF, Rozenberg F, Podglajen I, Marot S, Petit H, Burrel S, Akhavan S, Leruez-Ville M, Avettand-Fenoel V, Fourgeaud J, Guilleminot T, Gardiennet E, Bonacorsi S, Carol A, Carcelain G, Villemonteix J, Boukli N, Gozlan J, Morand-Joubert L, Legoff J, Delaugerre C, Chaix ML, Roque-Afonso AM, Dortet L, Naas T, Ronat JB, Lepape S, Marcelin AG, Descamps D
Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients.
European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 2021, 40, 2235-2241.
Husain M, Rachline A, Cousien A, Rolland S, Rouzaud C, Ferre VM, Gomez MV, Le Teurnier M, Wicky-Thisse M, Descamps D, Yazdanpanah Y, Charpentier C, Pasquet-Cadre A
Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020).
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2021, 27, 1520.e1-1520.e5.
Charpentier C, Pellissier G, Ichou H, Ferré VM, Larfi I, Phung BC, Vallois D, LeGac S, Aubier M, Descamps D, Fidouh-Houhou N, Bouvet E
Contribution of rapid lateral flow assays from capillary blood specimens to the diagnosis of COVID-19 in symptomatic healthcare workers: a pilot study in a university hospital, Paris, France.
Diagnostic Microbiology and Infectious Disease 2021, 101, 115430.
Lebourgeois S, Storto A, Gout B, Le Hingrat Q, Ardila Tjader G, Cerdan MDC, English A, Pareja J, Love J, Houhou-Fidouh N, Manissero D, Descamps D, Visseaux B
Performance evaluation of the QIAstat-Dx® Respiratory SARS-CoV-2 Panel.
International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2021, 107, 179-181.
Martin A, Storto A, Le Hingrat Q, Collin G, André B, Mallory A, Dangla R, Descamps D, Visseaux B, Gossner O
High-sensitivity SARS-CoV-2 group testing by digital PCR among symptomatic patients in hospital settings.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2021, 141, 104895.
Tubiana S, Burdet C, Houhou N, Thy M, Manchon P, Blanquart F, Charpentier C, Guedj J, Alavoine L, Behillil S, Leclercq A, Lucet JC, Yazdanpanah Y, Attia M, Demeret C, Rose T, Bielicki JA, Bruijning-Verhagen P, Goossens H, Descamps D, van der Werf S, Lina B, Duval X, CoVCONTACT study group, Principal investigator, Sponsor: Inserm
High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort.
The Journal of Infection 2021, 82, 186-230.
Teyssou E, Soulie C, Visseaux B, Lambert-Niclot S, Ferre V, Marot S, Jary A, Sayon S, Zafilaza K, Leducq V, Schnuriger A, Abdi B, Wirden M, Houhou-Fidouh N, Charpentier C, Morand-Joubert L, Burrel S, Descamps D, Calvez V, Marcelin AG
The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients.
The Journal of Infection 2021, 83, 119-145.
Teyssou E, Delagrèverie H, Visseaux B, Lambert-Niclot S, Brichler S, Ferre V, Marot S, Jary A, Todesco E, Schnuriger A, Ghidaoui E, Abdi B, Akhavan S, Houhou-Fidouh N, Charpentier C, Morand-Joubert L, Boutolleau D, Descamps D, Calvez V, Marcelin A, Soulie C
The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19.
The Journal of Infection 2021, S0163-4453(21)00416-3.
Visseaux B, Collin G, Houhou-Fidouh N, Le Hingrat Q, Ferré VM, Damond F, Ichou H, Descamps D, Charpentier C
Evaluation of three extraction-free SARS-CoV-2 RT-PCR assays: A feasible alternative approach with low technical requirements.
Journal of Virological Methods 2021, 291, 114086.
Fournier M, Faille D, Dossier A, Mageau A, Nicaise Roland P, Ajzenberg N, Borie R, Bouadma L, Bunel V, Castier Y, Choquet C, Crestani B, Daugas E, Deconinck L, Descamps D, Descamps V, Dieudé P, Ducrocq G, Faucher N, Goulenok T, Guidoux C, Khalil A, Lavallée P, Lescure FX, Lortat-Jacob B, Mal H, Mutuon P, Pellenc Q, Steg PG, Taille C, Timsit JF, Yazdanpanah Y, Papo T, Sacré K
Arterial Thrombotic Events in Adult Inpatients With COVID-19.
Mayo Clinic Proceedings 2021, 96, 295-303.
Flament H, Rouland M, Beaudoin L, Toubal A, Bertrand L, Lebourgeois S, Rousseau C, Soulard P, Gouda Z, Cagninacci L, Monteiro AC, Hurtado-Nedelec M, Luce S, Bailly K, Andrieu M, Saintpierre B, Letourneur F, Jouan Y, Si-Tahar M, Baranek T, Paget C, Boitard C, Vallet-Pichard A, Gautier JF, Ajzenberg N, Terrier B, Pène F, Ghosn J, Lescure X, Yazdanpanah Y, Visseaux B, Descamps D, Timsit JF, Monteiro RC, Lehuen A
Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity.
Nature Immunology 2021, 22, 322-335.
Berzow D, Descamps D, Obermeier M, Charpentier C, Kaiser R, Guertler L, Eberle J, Wensing A, Sierra S, Ruelle J, Gomes P, Mansinho K, Taylor N, Jensen B, Döring M, Stürmer M, Rockstroh J, Camacho R
Human Immunodeficiency Virus-2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2021, 72, 503-509.
Zucman N, Uhel F, Descamps D, Roux D, Ricard JD
Severe Reinfection With South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant 501Y.V2.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2021, 73, 1945-1946.
Tarhini H, Recoing A, Bridier-Nahmias A, Rahi M, Lambert C, Martres P, Lucet JC, Rioux C, Bouzid D, Lebourgeois S, Descamps D, Yazdanpanah Y, Le Hingrat Q, Lescure FX, Visseaux B
Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection.
The Journal of Infectious Diseases 2021, 223, 1522-1527.
Charpentier C, Storto A, Soulié C, Ferré VM, Wirden M, Joly V, Lambert-Niclot S, Palich R, Morand-Joubert L, Landman R, Lacombe K, Katlama C, Ghosn J, Marcelin AG, Calvez V, Descamps D
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
The Journal of Antimicrobial Chemotherapy 2021
Charpentier C, Storto A, Soulié C, Ferré VM, Wirden M, Joly V, Lambert-Niclot S, Palich R, Morand-Joubert L, Landman R, Lacombe K, Katlama C, Ghosn J, Marcelin AG, Calvez V, Descamps D
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2983-2987.
Bachelard A, Isernia V, Vallois D, Le Gac S, Chalal L, Landman R, Damond F, Descamps D, Yazdanpanah Y, Peytavin G, Ghosn J
Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2484-2485.
Marcelin AG, Charpentier C, Bellecave P, Abdi B, Chaix ML, Ferre V, Raymond S, Fofana D, Bocket L, Mirand A, Le Guillou-Guillemette H, Montes B, Amiel C, Pallier C, Fafi-Kremer S, De Monte A, Alessandri-Gradt E, Scholtes C, Maillard A, Jeulin H, Bouvier-Alias M, Roussel C, Dos Santos G, Signori-Schmuck A, Dina J, Vallet S, Stefic K, Soulié C, Calvez V, Descamps D, Flandre P, ANRS-MIE AC43 Group
Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2400-2406.
Martin C, Gracias S, Charpentier C, Descamps D, Le Hingrat Q, Plantier JC, Alessandri-Gradt E
HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2306-2309.
Bouzid D, Casalino E, Mullaert J, Laurent O, Duval X, Lescure FX, Peiffer Smadja N, Tubiana S, Armand Lefèvre L, Descamps D, Fidouh N, Choquet C, Lucet JC, Visseaux B
Added value of rapid respiratory syndromic testing at point of care versus central laboratory testing: a controlled clinical trial.
The Journal of Antimicrobial Chemotherapy 2021, 76, iii20-iii27.
Visseaux B, Bertine M, Le Hingrat Q, Ferré V, Charpentier C, Collin F, Damond F, Matheron S, Hué S, Descamps D
HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution.
Virus Evolution 2021, 7, veab024.
Le Hingrat Q, Bouzid D, Choquet C, Laurent O, Lescure FX, Timsit JF, Houhou-Fidouh N, Casalino E, Lucet JC, Descamps D, Visseaux B
Viral epidemiology and SARS-CoV-2 co-infections with other respiratory viruses during the first COVID-19 wave in Paris, France.
Influenza and Other Respiratory Viruses 2021, 15, 425-428.
Meyer A, Buetti N, Houhou-Fidouh N, Patrier J, Abdel-Nabey M, Jaquet P, Presente S, Girard T, Sayagh F, Ruckly S, Wicky PH, de Montmollin E, Bouadma L, Sonneville R, Descamps D, Timsit JF
HSV-1 reactivation is associated with an increased risk of mortality and pneumonia in critically ill COVID-19 patients.
Critical Care (London, England) 2021, 25, 417.
Bitty-Anderson AM, Ferré V, Gbeasor-Komlanvi FA, Tchankoni MK, Sadio A, Salou M, Descamps D, Dagnra CA, Charpentier C, Ekouevi DK, Coffie PA
Prevalence of hepatitis B and C among female sex workers in Togo, West Africa.
PloS One 2021, 16, e0259891.
Delaroche L, Bertine M, Oger P, Descamps D, Damond F, Genauzeau E, Meicler P, Le Hingrat Q, Lamazou F, Gschwind R, Ruppé E, Visseaux B
Evaluation of SARS-CoV-2 in semen, seminal plasma, and spermatozoa pellet of COVID-19 patients in the acute stage of infection.
PloS One 2021, 16, e0260187.
Lebourgeois S, Chenane HR, Houhou-Fidouh N, Menidjel R, Ferré VM, Collin G, Benmalek N, Coppée R, Larrouy L, Yazdanpanah Y, Timsit JF, Charpentier C, Descamps D, Visseaux B
Earlier In Vitro Viral Production With SARS-CoV-2 Alpha Than With Beta, Gamma, B, or A.27 Variants.
Frontiers in Cellular and Infection Microbiology 2021, 11, 792202.
Peiffer-Smadja N, Bridier-Nahmias A, Ferré VM, Charpentier C, Garé M, Rioux C, Allemand A, Lavallée P, Ghosn J, Kramer L, Descamps D, Yazdanpanah Y, Visseaux B
Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.
Viruses 2021, 13, 1642.
2020
Visseaux B, Hué S, Le Hingrat Q, Salmona M, Lebourgeois S, Delaugerre C, Descamps D, Chaix ML, Ghosn J
Phylogenetic investigation of HCV-4d epidemic in Paris MSM HIV population reveals a still active outbreak and a strong link to the Netherlands.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2020, 26, 785.e1-785.e4.
Peiffer-Smadja N, Lucet JC, Bendjelloul G, Bouadma L, Gerard S, Choquet C, Jacques S, Khalil A, Maisani P, Casalino E, Descamps D, Timsit JF, Yazdanpanah Y, Lescure FX
Challenges and issues about organising a hospital to respond to the COVID-19 outbreak: experience from a French reference centre.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2020
Hingrat QL, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y, Duval X, Burdet C, Ichou H, Damond F, Bertine M, Benmalek N, Choquet C, Timsit JF, Ghosn J, Charpentier C, Descamps D, Houhou-Fidouh N, French COVID cohort management committee, CoV-CONTACT study group, members of the French-COVID cohort study group (by alphabetical order), member of the CoV-CONTACT study group. Principal investigator, Steering Committee, CoV-CONTACT Clinical Centers, Coordination and statistical analyses, Virological Lab, Biological Center, Partners, Sponsor, Genetic
Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2020, S1198-743X(20)30721-7.
Battesti G, El Khalifa J, Abdelhedi N, Ferre V, Bouscarat F, Picard-Dahan C, Brunet-Possenti F, Collin G, Lavaud J, Le Bozec P, Rousselot M, Tournier A, Lheure C, Couvelard A, Hacein-Bey-Abina S, Abina AM, Charpentier C, Mignot S, Nicaise P, Descamps D, Deschamps L, Descamps V
New insights in COVID-19–associated chilblains: A comparative study with chilblain lupus erythematosus.
Journal of the American Academy of Dermatology 2020, 83, 1219-1222.
Visseaux B, Le Hingrat Q, Collin G, Ferré V, Storto A, Ichou H, Bouzid D, Poey N, de Montmollin E, Descamps D, Houhou-Fidouh N
Evaluation of the RealStar® SARS-CoV-2 RT-PCR kit RUO performances and limit of detection.
Journal of Clinical Virology 2020, 129, 104520.
Wirden M, Feghoul L, Bertine M, Nere ML, Le Hingrat Q, Abdi B, Boutolleau D, Ferre VM, Jary A, Delaugerre C, Marcelin AG, Descamps D, Legoff J, Visseaux B, Chaix ML
Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2020, 130, 104573.
Charpentier C, Ichou H, Damond F, Bouvet E, Chaix ML, Ferré V, Delaugerre C, Mahjoub N, Larrouy L, Le Hingrat Q, Visseaux B, Mackiewicz V, Descamps D, Fidouh-Houhou N
Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott).
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2020, 132, 104618.
Cancella de Abreu M, Choquet C, Petit H, Bouzid D, Damond F, Marot S, Ferre VM, Burrel S, Boutolleau D, Houdou-Fidouh N, Marcelin AG, Descamps D, Hausfater P
SARS-CoV-2 IGM and IGG rapid serologic test for the diagnosis of COVID-19 in the emergency department.
The Journal of Infection 2020, 81, 816-846.
San C, Lê MP, Matheron S, Mourvillier B, Caseris M, Timsit JF, Wolff M, Yazdanpanah Y, Descamps D, Peytavin G
Management of oral antiretroviral administration in patients with swallowing disorders or with an enteral feeding tube.
Medecine Et Maladies Infectieuses 2020, 50, 537-544.
Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A, Bouscambert-Duchamp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y
Clinical and virological data of the first cases of COVID-19 in Europe: a case series.
The Lancet. Infectious Diseases 2020, 20, 697-706.
Triki D, Kermarrec M, Visseaux B, Descamps D, Flatters D, Camproux AC, Regad L
Exploration of the effects of sequence variations between HIV-1 and HIV-2 proteases on their three-dimensional structures.
Journal of Biomolecular Structure & Dynamics 2020, 38, 5014-5026.
Tzou PL, Descamps D, Rhee SY, Raugi DN, Charpentier C, Taveira N, Smith RA, Soriano V, de Mendoza C, Holmes SP, Gottlieb GS, Shafer RW
Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.
The Journal of Infectious Diseases 2020, 221, 1962-1972.
Jary A, Leducq V, Desire N, Petit H, Palich R, Joly V, Canestri A, Gothland A, Lambert-Niclot S, Surgers L, Amiel C, Descamps D, Spano JP, Katlama C, Calvez V, Marcelin AG
New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies.
The Journal of Infectious Diseases 2020, 222, 1320-1328.
Jary A, Marcelin AG, Charpentier C, Wirden M, Lê MP, Peytavin G, Descamps D, Calvez V
M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.
The Journal of Antimicrobial Chemotherapy 2020, 75, 1290-1293.
Charpentier C, Peytavin G, Raffi F, Burdet C, Landman R, Lê MP, Katlama C, Collin G, Benalycherif A, Cabie A, Mentré F, Yazdanpanah Y, Descamps D, Joly V
Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
The Journal of Antimicrobial Chemotherapy 2020, 75, 1611-1617.
Marcelin AG, Charpentier C, Jary A, Perrier M, Margot N, Callebaut C, Calvez V, Descamps D
Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients.
The Journal of Antimicrobial Chemotherapy 2020, 75, 1588-1590.
Soulie C, Assoumou L, Abdi B, Sayon S, Nguyen T, Valantin MA, Beniguel L, Ferre V, Alloui C, Montes B, Avettand-Fenoel V, Delaugerre C, Descamps D, Martinez E, Reynes J, Peytavin G, Costagliola D, Katlama C, Calvez V, Marcelin AG, A1Esg
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
The Journal of Antimicrobial Chemotherapy 2020, 75, 1943-1949.
Soulie C, Assoumou L, Abdi B, Sayon S, Nguyen T, Valantin MA, Beniguel L, Ferre V, Alloui C, Montes B, Avettand-Fenoel V, Delaugerre C, Descamps D, Martinez E, Reynes J, Peytavin G, Costagliola D, Katlama C, Calvez V, Marcelin AG, ANRS-163 ETRAL study group
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
The Journal of Antimicrobial Chemotherapy 2020, 75, 1943-1949.
Kauv J, Lê MP, Veyrier M, Le Hingrat Q, Visseaux B, Massias L, Chauveheid MP, Descamps D, Ghosn J, Peytavin G
Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report.
The Journal of Antimicrobial Chemotherapy 2020, 75, 2706-2707.
Lê MP, Jaquet P, Patrier J, Wicky PH, Le Hingrat Q, Veyrier M, Kauv J, Sonneville R, Visseaux B, Laouénan C, Bouadma L, Descamps D, de Montmollin E, Peytavin G, Timsit JF
Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients.
The Journal of Antimicrobial Chemotherapy 2020, 75, 2657-2660.
Visseaux B, Assoumou L, Mahjoub N, Grude M, Trabaud MA, Raymond S, Wirden M, Morand-Joubert L, Roussel C, Montes B, Bocket L, Fafi-Kremer S, Amiel C, De Monte A, Stefic K, Pallier C, Tumiotto C, Maillard A, Vallet S, Ferre V, Bouvier-Alias M, Dina J, Signori-Schmuck A, Carles MJ, Plantier JC, Meyer L, Descamps D, Chaix ML, AARG
Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?.
The Journal of Antimicrobial Chemotherapy 2020, 75, 183-193.
Visseaux B, Assoumou L, Mahjoub N, Grude M, Trabaud MA, Raymond S, Wirden M, Morand-Joubert L, Roussel C, Montes B, Bocket L, Fafi-Kremer S, Amiel C, De Monte A, Stefic K, Pallier C, Tumiotto C, Maillard A, Vallet S, Ferre V, Bouvier-Alias M, Dina J, Signori-Schmuck A, Carles MJ, Plantier JC, Meyer L, Descamps D, Chaix ML, AC43 ANRS Resistance Group
Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?.
The Journal of Antimicrobial Chemotherapy 2020, 75, 183-193.
Tzou PL, Rhee SY, Descamps D, Clutter DS, Hare B, Mor O, Grude M, Parkin N, Jordan MR, Bertagnolio S, Schapiro JM, Harrigan PR, Geretti AM, Marcelin AG, Shafer RW, WHO HIVResNet Working Groups
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
The Journal of Antimicrobial Chemotherapy 2020, 75, 170-182.
Soulie C, Santoro MM, Storto A, Abdi B, Charpentier C, Armenia D, Jary A, Forbici F, Bertoli A, Gennari W, Andreoni M, Mussini C, Antinori A, Perno CF, Calvez V, Ceccherini-Silberstein F, Descamps D, Marcelin AG
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
The Journal of Antimicrobial Chemotherapy 2020, 75, 1026-1030.
Bello G, Delatorre E, Lacoste V, Darcissac E, Herrmann-Storck C, Tressières B, Cabras O, Lamaury I, Cabié A, Visseaux B, Chaix ML, Descamps D, Césaire R, Nacher M, Dos Santos G
Increasing prevalence and local transmission of non-B HIV-1 subtypes in the French Antilles and French Guiana between 1995 and 2018.
Virus Evolution 2020, 6, veaa081.
Néant N, Lê MP, Bouazza N, Gattacceca F, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Solas C
Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients.
British Journal of Clinical Pharmacology 2020, 86, 2404-2413.
Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, Guivel-Benhassine F, Staropoli I, Chazal M, Dufloo J, Planas D, Buchrieser J, Rajah MM, Robinot R, Porrot F, Albert M, Chen KY, Crescenzo-Chaigne B, Donati F, Anna F, Souque P, Gransagne M, Bellalou J, Nowakowski M, Backovic M, Bouadma L, Le Fevre L, Le Hingrat Q, Descamps D, Pourbaix A, Laouénan C, Ghosn J, Yazdanpanah Y, Besombes C, Jolly N, Pellerin-Fernandes S, Cheny O, Ungeheuer MN, Mellon G, Morel P, Rolland S, Rey FA, Behillil S, Enouf V, Lemaitre A, Créach MA, Petres S, Escriou N, Charneau P, Fontanet A, Hoen B, Bruel T, Eloit M, Mouquet H, Schwartz O, van der Werf S
A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations.
Science Translational Medicine 2020, 12,
Lê MP, Le Hingrat Q, Jaquet P, Wicky PH, Bunel V, Massias L, Visseaux B, Messika J, Descamps D, Mal H, Timsit JF, Peytavin G
Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19.
Antimicrobial Agents and Chemotherapy 2020, 64,
Lê MP, Le Beller C, Le Hingrat Q, Jaquet P, Wicky PH, Bunel V, Massias L, Visseaux B, Messika J, Descamps D, Mal H, Timsit JF, Peytavin G
Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity".
Antimicrobial Agents and Chemotherapy 2020, 64,
Visseaux B, Le Hingrat Q, Collin G, Bouzid D, Lebourgeois S, Le Pluart D, Deconinck L, Lescure FX, Lucet JC, Bouadma L, Timsit JF, Descamps D, Yazdanpanah Y, Casalino E, Houhou-Fidouh N, McAdam AJ
Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection.
Journal of Clinical Microbiology 2020, 58, e00630-20, /jcm/58/8/JCM.00630-20.atom.
Le Hingrat Q, Visseaux B, Bertine M, Chauveau L, Schwartz O, Collin F, Damond F, Matheron S, Descamps D, Charpentier C
Genetic Variability of Long Terminal Repeat Region between HIV-2 Groups Impacts Transcriptional Activity.
Journal of Virology 2020, 94,
Le Hingrat Q, Ghanem M, Cazes A, Visseaux B, Collin G, Descamps D, Charpentier C, Crestani B
No association between human herpesvirus or herpesvirus saimiri and idiopathic pulmonary fibrosis.
ERJ Open Research 2020, 6, 00243-2020.
Ekouevi DK, Larrouy L, Gbeasor-Komlanvi FA, Mackiewicz V, Tchankoni MK, Bitty-Anderson AM, Gnatou GYS, Sadio A, Salou M, Dagnra CA, Descamps D, Coffie PA
Prevalence of hepatitis B among childbearing women and infant born to HBV-positive mothers in Togo.
BMC infectious diseases 2020, 20, 839.
Tchounga BK, Charpentier C, Coffie PA, Dabis F, Descamps D, Eholie SP, Ekouevi DK
Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.
PloS One 2020, 15, e0236642.
Bouzid D, Mullaert J, Le Hingrat Q, Laurent O, Duval X, Lescure X, Timsit JF, Descamps D, Montravers P, Choquet C, Lucet JC, Casalino E, Visseaux B, ED influenza study group
Characteristics associated with COVID-19 or other respiratory viruses' infections at a single-center emergency department.
PloS One 2020, 15, e0243261.
Borie R, Savale L, Dossier A, Ghosn J, Taillé C, Visseaux B, Jebreen K, Diallo A, Tesmoingt C, Morer L, Goletto T, Faucher N, Hajouji L, Neukirch C, Phillips M, Stelianides S, Bouadma L, Brosseau S, Ottaviani S, Pluvy J, Le Pluart D, Debray MP, Raynaud-Simon A, Descamps D, Khalil A, Timsit JF, Lescure FX, Descamps V, Papo T, Humbert M, Crestani B, Dieude P, Vicaut E, Zalcman G, Bichat & Kremlin-Bicêtre AP-HP COVID teams
Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study.
PloS One 2020, 15, e0243961.
Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM, Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D, Houhou-Fidouh N, Reusken CBEM, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.
Emerging Infectious Diseases 2020, 26,
Iannetta M, Isnard S, Manuzak J, Guillerme JB, Notin M, Bailly K, Andrieu M, Amraoui S, Vimeux L, Figueiredo S, Charmeteau-de Muylder B, Vaton L, Hatton EX, Samri A, Autran B, Thiébaut R, Chaghil N, Glohi D, Charpentier C, Descamps D, Brun-Vézinet F, Matheron S, Cheynier R, Hosmalin A
Conventional Dendritic Cells and Slan+ Monocytes During HIV-2 Infection.
Frontiers in Immunology 2020, 11, 1658.
2019
Brunet-Possenti F, Charpentier C, Bouhnik Y, Deschamps L, Descamps D, Moins-Teisserenc H, Descamps V
Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy.
JAMA Dermatology 2019, 155, 629.
Ferré V, Ekouevi D, Gbeasor-Komlanvi F, Collin G, Le Hingrat Q, Tchounga B, Salou M, Descamps D, Charpentier C, Dagnra A
Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey.
Clinical Microbiology and Infection 2019, 25, 1560.e1-1560.e7.
Le Hingrat Q, Perrier M, Charpentier C, Jacquot A, Houhou-Fidouh N, Descamps D, Visseaux B
Was Zika introduced to Brazil by participants at the 2013 Beach Soccer World Cup held in Tahiti: A phylogeographical analysis.
Travel Medicine and Infectious Disease 2019, 101512.
Le Hingrat Q, Charpentier C, Ghosn J, Thiébaut R, Peytavin G, Descamps D, Matheron S
New insights are game-changers in HIV-2 disease management.
The lancet. HIV 2019, 6, e214.
Triki D, Fartek S, Visseaux B, Descamps D, Camproux AC, Regad L
Characterizing the structural variability of HIV-2 protease upon the binding of diverse ligands using a structural alphabet approach.
Journal of Biomolecular Structure & Dynamics 2019, 37, 4658-4670.
Ferré VM, Gbeasor-Komlanvi FA, Collin G, Dagnra AC, Le Hingrat Q, Jaquet A, Salou M, Descamps D, Charpentier C, Ekouevi DK
Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019, 69, 1019-1026.
Le Hingrat Q, Collin G, Lê M, Peytavin G, Visseaux B, Bertine M, Tubiana R, Karmochkine M, Valin N, Collin F, Lemaignen A, Bernard L, Damond F, Matheron S, Descamps D, Charpentier C, FNAfRoAaVH(CH2C
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019, 69, 657-667.
Le Hingrat Q, Collin G, Lê M, Peytavin G, Visseaux B, Bertine M, Tubiana R, Karmochkine M, Valin N, Collin F, Lemaignen A, Bernard L, Damond F, Matheron S, Descamps D, Charpentier C, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO5 HIV-2 Cohort
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019, 69, 657-667.
Ngo-Giang-Huong N, Huynh THK, Dagnra AY, Toni Td, Maiga AI, Kania D, Eymard-Duvernay S, Peeters M, Soulie C, Peytavin G, Rekacewicz C, Chaix ML, Aghokeng AF, ANRS 12333 Study Group, Aghokeng AF, Ayouba A, Brun-Vézinet F, Chaix ML, Calvez V, Dagnra A, Descamps D, Dramane K, Fournier I, Maiga A, de Monteynard LA, Nouhin J, Kane CT, Lien TX, Ngo-Giang-Huong N, Peeters M, Plantier JC, Njouom R, Tuaillon E, Rekacewicz C, d’Aquin TT, Poda A, Zougrana J, Ouedraogo S, Ouedraogo M, Djeuda AD, Kouanfack C, Mandeng N, Mpoudi-Ngole E, Messou E, Jacques DJ, Nguessan JF, Dolo O, Diarra Z, Cisse M, Patassi A, Salou M, Ali-Edjé K, Bowonwatanuwong C, Thongpaen S, Klinbuayaem V, Laomanit L, Luong QA, Tran T
Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries.
Journal of Antimicrobial Chemotherapy 2019, 74, 462-467.
Soulie C, Santoro MM, Charpentier C, Storto A, Paraskevis D, Di Carlo D, Gennari W, Sterrantino G, Zazzi M, Perno CF, Calvez V, Descamps D, Ceccherini-Silberstein F, Marcelin AG
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.
The Journal of Antimicrobial Chemotherapy 2019, 74, 614-617.
Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y, LAMIDOL Study Group
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
The Journal of Antimicrobial Chemotherapy 2019, 74, 739-745.
Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D, ANRS AC-43 Resistance Study Group
Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1417-1424.
Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D, AA4RSG
Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1417-1424.
Marcelin AG, Grude M, Charpentier C, Bellecave P, Le Guen L, Pallier C, Raymond S, Mirand A, Bocket L, Fofana DB, Delaugerre C, Nguyen T, Montès B, Jeulin H, Mourez T, Fafi-Kremer S, Amiel C, Roussel C, Dina J, Trabaud MA, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Maillard A, Ferre V, Descamps D, Calvez V, Flandre P, AARG
Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1368-1375.
Marcelin AG, Grude M, Charpentier C, Bellecave P, Le Guen L, Pallier C, Raymond S, Mirand A, Bocket L, Fofana DB, Delaugerre C, Nguyen T, Montès B, Jeulin H, Mourez T, Fafi-Kremer S, Amiel C, Roussel C, Dina J, Trabaud MA, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Maillard A, Ferre V, Descamps D, Calvez V, Flandre P, ANRS AC43 Resistance Group
Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1368-1375.
Perrier M, Castain L, Regad L, Todesco E, Landman R, Visseaux B, Yazdanpanah Y, Rodriguez C, Joly V, Calvez V, Marcelin AG, Descamps D, Charpentier C
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1679-1692.
Néant N, Solas C, Bouazza N, Lê MP, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Gattacceca F
Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1992-2002.
Castain L, Perrier M, Charpentier C, Palich R, Desire N, Wirden M, Descamps D, Sayon S, Landman R, Valantin MA, Joly V, Peytavin G, Yazdanpanah Y, Katlama C, Calvez V, Marcelin AG, Todesco E
New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
The Journal of Antimicrobial Chemotherapy 2019, 74, 2019-2023.
Pommier JD, Laouénan C, Michard F, Papot E, Urios P, Boutten A, Peytavin G, Ghander C, Lariven S, Castanedo G, Moho D, Landman R, Phung B, Perez E, Julia Z, Descamps D, Roland-Nicaise P, Le Gac S, Yazdanpanah Y, Guibourdenche J, Yeni P
Metabolic syndrome and endocrine status in HIV-infected transwomen.
AIDS (London, England) 2019, 33, 855-865.
Visseaux B, Le Hingrat Q, Damond F, Charpentier C, Descamps D
[Physiopathology of HIV-2 infection].
Virologie (Montrouge, France) 2019, 23, 277-291.
van de Laar MJ, Bosman A, Pharris A, Andersson E, Assoumou L, Ay E, Bannert N, Bartmeyer B, Brady M, Chaix ML, Descamps D, Dauwe K, Fonager J, Hauser A, Lunar M, Mezei M, Neary M, Poljak M, van Sighem A, Verhofstede C, Amato-Gauci AJ, Broberg EK
Piloting a surveillance system for HIV drug resistance in the European Union.
Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 2019, 24,
Wirden M, De Oliveira F, Bouvier-Alias M, Lambert-Niclot S, Chaix ML, Raymond S, Si-Mohammed A, Alloui C, André-Garnier E, Bellecave P, Malve B, Mirand A, Pallier C, Poveda JD, Rabenja T, Schneider V, Signori-Schmuck A, Stefic K, Calvez V, Descamps D, Plantier JC, Marcelin AG, Visseaux B, On Behalf Of The French National Agency For Research On Aids And Viral Hepatitis Anrs Ac Study Group n
New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017.
Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 2019, 24,
2018
Néant N, Gattacceca F, Lê MP, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Solas C
Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.
European Journal of Clinical Pharmacology 2018, 74, 473-481.
Le Hingrat Q, Perrier M, Collin G, Drumard S, Storto A, Bertine M, Larrouy L, Matheron S, Damond F, Charpentier C, Descamps D, Visseaux B
Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads.
Journal of Virological Methods 2018, 257, 12-15.
Triki D, Cano Contreras ME, Flatters D, Visseaux B, Descamps D, Camproux AC, Regad L
Analysis of the HIV-2 protease's adaptation to various ligands: characterization of backbone asymmetry using a structural alphabet.
Scientific Reports 2018, 8, 710.
Triki D, Billot T, Visseaux B, Descamps D, Flatters D, Camproux AC, Regad L
Exploration of the effect of sequence variations located inside the binding pocket of HIV-1 and HIV-2 proteases.
Scientific Reports 2018, 8, 5789.
Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud MA, Morand-Joubert L, Rodallec A, Amiel C, Mourez T, Bocket L, Beby-Defaux A, Bouvier-Alias M, Lambert-Niclot S, Charpentier C, Malve B, Mirand A, Dina J, Le Guillou-Guillemette H, Marque-Juillet S, Signori-Schmuck A, Barin F, Si-Mohamed A, Avettand Fenoel V, Roussel C, Calvez V, Saune K, Marcelin AG, Rodriguez C, Descamps D, Izopet J, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group
Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2018, 66, 1588-1594.
Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L, Mortier E, Charpentier C, Tubiana R, Damond F, Peytavin G, Ponscarme D, Collin F, Brun-Vezinet F, Chene G, France REcherche Nord&Sud Sida-Hiv Hépatites (ANRS) 159 HIV-2 Trial Study Group
First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2018, 67, 1161-1167.
Mariaggi AA, Péré H, Perrier M, Visseaux B, Collin G, Veyer D, Le Hingrat Q, Ferré VM, Joly V, Couvelard A, Bucau M, Davitian C, Descamps D, Abramowitz L, Charpentier C
Presence of Human Papillomavirus (HPV) Apolipoprotein B Messenger RNA Editing, Catalytic Polypeptide-Like 3 (APOBEC)-Related Minority Variants in HPV-16 Genomes From Anal and Cervical Samples but Not in HPV-52 and HPV-58.
The Journal of Infectious Diseases 2018, 218, 1027-1036.
Perrier M, Visseaux B, Landman R, Joly V, Todesco E, Yazdanpanah Y, Calvez V, Marcelin AG, Descamps D, Charpentier C
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
The Journal of Antimicrobial Chemotherapy 2018, 73, 173-176.
Le Meur L, Tantet C, Lê MP, Desselas E, Bonnal C, Lillo-Le-Louet A, Sonneville R, Massias L, Giraud J, Descamps D, Yazdanpanah Y, Lariven S, Peytavin G
Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis.
The Journal of Antimicrobial Chemotherapy 2018, 73, 1108-1110.
Charpentier C, Malet I, Andre-Garnier E, Storto A, Bocket L, Amiel C, Morand-Joubert L, Tumiotto C, Nguyen T, Maillard A, Rodallec A, Leoz M, Montes B, Schneider V, Plantier JC, Dina J, Pallier C, Mirand A, Roussel C, Signori-Schmuck A, Raymond S, Calvez V, Delaugerre C, Marcelin AG, Descamps D
Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.
The Journal of Antimicrobial Chemotherapy 2018, 73, 1039-1044.
Storto A, Visseaux B, Bertine M, Le Hingrat Q, Collin G, Damond F, Khuong MA, Blum L, Tubiana R, Karmochkine M, Cazanave C, Matheron S, Descamps D, Charpentier C, ANRS HIV-2 CO5 Cohort
Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2018
Charpentier C, Peytavin G, Lê MP, Joly V, Cabras O, Perrier M, Le Gac S, Phung B, Yazdanpanah Y, Descamps D, Landman R
High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.
The Journal of Antimicrobial Chemotherapy 2018, 73, 1665-1671.
Lambert-Niclot S, Grude M, Chaix ML, Charpentier C, Reigadas S, Le Guillou-Guillemette H, Rodallec A, Amiel C, Maillard A, Dufayard J, Mourez T, Mirand A, Guinard J, Montes B, Vallet S, Marcelin AG, Descamps D, Flandre P, Delaugerre C, Morand-Joubert L, ANRS AC-11 Resistance Group
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
The Journal of Antimicrobial Chemotherapy 2018
Nguyen T, Fofana DB, Lê MP, Charpentier C, Peytavin G, Wirden M, Lambert-Niclot S, Desire N, Grude M, Morand-Joubert L, Flandre P, Katlama C, Descamps D, Calvez V, Todesco E, Marcelin AG
Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing.
The Journal of Antimicrobial Chemotherapy 2018, 73, 2485-2492.
Alessandri-Gradt E, Charpentier C, Leoz M, Mourez T, Descamps D, Plantier JC
Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.
The Journal of Antimicrobial Chemotherapy 2018
Cazals N, Le Hingrat Q, Abraham B, Da Silva P, Guindre L, Goffart S, Damond F, Visseaux B, Charpentier C, Ranger-Rogez S, Descamps D
HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man.
Open Forum Infectious Diseases 2018, 5, ofy223.
Brunet-Possenti F, Charpentier C, Collin G, Descamps D, Descamps V
Impact of anti-interleukin-17 treatment on cutaneous and genital human papillomavirus infection.
The British Journal of Dermatology 2018, 179, 1179-1180.
Pouga L, Mercedes Santoro M, Charpentier C, Di Carlo D, Romeo I, Artese A, Alcaro S, Antinori A, Wirden M, Perno CF, Ambrosio FA, Calvez V, Descamps D, Marcelin AG, Ceccherini-Silberstein F, Lambert-Niclot S
New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T).
Chemical Biology & Drug Design 2018
Gallien S, Massetti M, Flandre P, Leleu H, Descamps D, Lazaro E
Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis.
HIV medicine 2018
Jary A, Leducq V, Palich R, Gothland A, Descamps D, Joly V, Lambert-Niclot S, Amiel C, Canestri A, Mirand A, Gault E, Vabret A, Valantin MA, Katlama C, Calvez V, Dupin N, Spano JP, Marcelin AG
Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases.
Journal of Clinical Microbiology 2018, 56,
Désiré N, Cerutti L, Le Hingrat Q, Perrier M, Emler S, Calvez V, Descamps D, Marcelin AG, Hué S, Visseaux B
Characterization update of HIV-1 M subtypes diversity and proposal for subtypes A and D sub-subtypes reclassification.
Retrovirology 2018, 15, 80.
Perrier M, Désiré N, Storto A, Todesco E, Rodriguez C, Bertine M, Le Hingrat Q, Visseaux B, Calvez V, Descamps D, Marcelin AG, Charpentier C
Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants.
PloS One 2018, 13, e0198334.
Charpentier C, Descamps D
Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.
Viruses 2018, 10,
2017
Loubet P, Voiriot G, Houhou-Fidouh N, Neuville M, Bouadma L, Lescure FX, Descamps D, Timsit JF, Yazdanpanah Y, Visseaux B
Impact of respiratory viruses in hospital-acquired pneumonia in the intensive care unit: A single-center retrospective study.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2017, 91, 52-57.
Wirden M, Larrouy L, Mahjoub N, Todesco E, Damond F, Delagreverie H, Akhavan S, Charpentier C, Chaix ML, Descamps D, Calvez V, Marcelin AG
Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2017, 96, 49-53.
Mamede JI, Damond F, Bernardo Ad, Matheron S, Descamps D, Battini JL, Sitbon M, Courgnaud V
Cyclophilins and nucleoporins are required for infection mediated by capsids from circulating HIV-2 primary isolates.
Scientific Reports 2017, 7, 45214.
Senard O, Burdet C, Visseaux B, Charpentier C, Le Gac S, Julia Z, Lariven S, Descamps D, Yazdanpanah Y, Yeni P, Joly V
Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study.
AIDS Res Hum Retroviruses 2017, 33, 11-16.
Unal G, Alessandri-Gradt E, Leoz M, Pavie J, Lefevre C, Panjo H, Charpentier C, Descamps D, Barin F, Simon F, Meyer L, Plantier JC
HIV-1 group O infection in France: clinical features and immunovirological response to antiretrovirals.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2017
Briand C, Dollfus C, Faye A, Kantor E, Avettand-Fenoel V, Caseris M, Descamps D, Schneider V, Tabone MD, Vaudre G, Veber F, Blanche S, Frange P
Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study.
The Journal of Antimicrobial Chemotherapy 2017, 72, 837–843.
Wirden M, Charpentier C, Tubiana R, Le MP, Desire N, Dionou S, Pichon F, Valantin MA, Yasdanpanah Y, Descamps D, Peytavin G, Katlama C, Calvez V, Marcelin AG
HIV-1 diagnosis with unquantifiable viraemia: don't be naive, look for antiretroviral drugs.
The Journal of Antimicrobial Chemotherapy 2017, 72, 630-632.
Madelain V, Le MP, Champenois K, Charpentier C, Landman R, Joly V, Yeni P, Descamps D, Yazdanpanah Y, Peytavin G
Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1137-1146.
Perrier M, Charpentier C, Peytavin G, Lê M, Blondel L, Visseaux B, Joly V, Pinto A, Matheron S, Yazdanpanah Y, Descamps D, Landman R
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1745-1751.
Assoumou L, Charpentier C, Recordon-Pinson P, Grudé M, Pallier C, Morand-Joubert L, Fafi-Kremer S, Krivine A, Montes B, Ferré V, Bouvier-Alias M, Plantier JC, Izopet J, Trabaud MA, Yerly S, Dufayard J, Alloui C, Courdavault L, Le Guillou-Guillemette H, Maillard A, Amiel C, Vabret A, Roussel C, Vallet S, Guinard J, Mirand A, Beby-Defaux A, Barin F, Allardet-Servent A, Ait-Namane R, Wirden M, Delaugerre C, Calvez V, Chaix ML, Descamps D, Reigadas S, ANRS AC-11 Resistance Study Group
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1769-1773.
Soulie C, Grudé M, Descamps D, Amiel C, Morand-Joubert L, Raymond S, Pallier C, Bellecave P, Reigadas S, Trabaud MA, Delaugerre C, Montes B, Barin F, Ferré V, Jeulin H, Alloui C, Yerly S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG, ANRS AC11 Resistance Study Group
Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2351-2354.
Alessandri-Gradt E, Collin G, Tourneroche A, Bertine M, Leoz M, Charpentier C, Unal G, Descamps D, Plantier JC
HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2431-2437.
Perrier M, Bertine M, Le Hingrat Q, Joly V, Visseaux B, Collin G, Landman R, Yazdanpanah Y, Descamps D, Charpentier C
Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2954-2955.
Todesco E, Charpentier C, Bertine M, Wirden M, Storto A, Desire N, Grude M, Nguyen T, Sayon S, Yazdanpanah Y, Katlama C, Descamps D, Calvez V, Marcelin AG
Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations.
HIV medicine 2017, 18, 696-700.
Bertine M, Gueudin M, Mélard A, Damond F, Descamps D, Matheron S, Collin F, Rouzioux C, Plantier JC, Avettand-Fenoel V
New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification.
Journal of Clinical Microbiology 2017, 55, 2850-2857.
Malet I, Subra F, Charpentier C, Collin G, Descamps D, Calvez V, Marcelin AG, Delelis O
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
mBio 2017
Visseaux B, Collin G, Ichou H, Charpentier C, Bendhafer S, Dumitrescu M, Allal L, Cojocaru B, Desfrère L, Descamps D, Mandelbrot L, Houhou-Fidouh N
Usefulness of multiplex PCR methods and respiratory viruses' distribution in children below 15 years old according to age, seasons and clinical units in France: A 3 years retrospective study.
PloS One 2017, 12, e0172809.
Visseaux B, Burdet C, Voiriot G, Lescure FX, Chougar T, Brugiere O, Crestani B, Casalino E, Charpentier C, Descamps D, Timsit JF, Yazdanpanah Y, Houhou-Fidouh N
Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016.
PLoS One 2017, 12, e0180888.
2016
Delory T, Papot E, Rioux C, Charpentier C, Auge-Courtoi C, Michard F, Peytavin G, Descamps D, Matheron S, Yazdanpanah Y
Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.
Journal of Medical Virology 2016, 88, 1204-1210.
Desnoyer A, Pospai D, Lê MP, Gervais A, Heurgué-Berlot A, Laradi A, Harent S, Pinto A, Salmon D, Hillaire S, Fontaine H, Zucman D, Simonpoli AM, Muret P, Larrouy L, Bernard Chabert B, Descamps D, Yazdanpanah Y, Peytavin G
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
Journal of Hepatology 2016, 65, 40-47.
Visseaux B, Damond F, Matheron S, Descamps D, Charpentier C
Hiv-2 molecular epidemiology.
Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 2016, 46, 233-240.
Benmoussa N, Charpentier C, Mariaggi AA, Collin G, Descamps D, Hourseau M, Barry B, Albert S, Picard A, Conan P, Charlier P
HPV 16 in squamous cell carcinoma of 19th century tonsils.
The Lancet. Oncology 2016, 17, e477–e478.
Visseaux B, Mortier E, Houhou-Fidouh N, Brichler S, Collin G, Larrouy L, Charpentier C, Descamps D
Zika virus in the female genital tract.
The Lancet. Infectious Diseases 2016, 16, 1220.
Frange P, Faye A, Avettand-Fenoël V, Bellaton E, Descamps D, Angin M, David A, Caillat-Zucman S, Peytavin G, Dollfus C, Le Chenadec J, Warszawski J, Rouzioux C, Sáez-Cirión A, ANRS EPF-CO10 Pediatric Cohort and the ANRS EP47 VISCONTI study group
HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.
The lancet. HIV 2016, 3, e49–54.
D'Ortenzio E, Matheron S, Yazdanpanah Y, de Lamballerie X, Hubert B, Piorkowski G, Maquart M, Descamps D, Damond F, Leparc-Goffart I
Evidence of Sexual Transmission of Zika Virus.
The New England Journal of Medicine 2016, 374, 2195-2198.
Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ, SPREAD Program
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2016, 62, 655–663.
De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, Günthard HF, Wittkop L, Kordossis T, Garcia F, Castagna A, Cozzi-Lepri A, Churchill D, De Wit S, Brockmeyer NH, Imaz A, Mussini C, Obel N, Perno CF, Roca B, Reiss P, Schülter E, Torti C, van Sighem A, Zangerle R, Descamps D, CHAIN and COHERE in EuroCoord
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.
The Journal of Antimicrobial Chemotherapy 2016, 71, 1352–1360.
Bocket L, Peytavin G, Alidjinou EK, Ajana F, Choisy P, Lê M, Charpentier C, Descamps D, Yazdanpanah Y, Katlama C, Simon A, Calvez V, Marcelin AG, Soulie C
Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
The Journal of Antimicrobial Chemotherapy 2016, 71, 2651-2653.
Bertine M, Visseaux B, Storto A, Collin G, Matheron S, Descamps D, Charpentier C, ANRS CO5 HIV-2 Cohort
HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
Journal of Acquired Immune Deficiency Syndromes (1999) 2016, 72, e9–e11.
2015
Soulie C, Peytavin G, Charpentier C, Lambert-Niclot S, Sayon S, Visseaux B, Simon A, Katlama C, Yazdanpanah Y, Descamps D, Calvez V, Marcelin AG
Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.
AIDS research and human retroviruses 2015, 31, 475-478.
Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, Charpentier C, Khuong-Josses MA, Duvivier C, Karmochkine M, Lukiana T, Matheron S
Dolutegravir in HIV-2 infected patients with resistant virus to first-line integrase inhibitors from the French Named Patient Program.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2015
Charpentier C, Camacho R, Ruelle J, Eberle J, Gürtler L, Pironti A, Stürmer M, Brun-Vézinet F, Kaiser R, Descamps D, Obermeier M
HIV-2EU-Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2015, 61, 1346–1347.
Fofana DB, Charpentier C, Maïga AI, Lambert-Niclot S, Sayon S, Désiré N, Simon A, Yazdanpanah Y, Katlama C, Descamps D, Calvez V, Marcelin AG, Soulié C
Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
The Journal of Antimicrobial Chemotherapy 2015, 70, 130-135.
Fourati S, Charpentier C, Amiel C, Morand-Joubert L, Reigadas S, Trabaud MA, Delaugerre C, Nicot F, Rodallec A, Maillard A, Mirand A, Jeulin H, Montès B, Barin F, Bettinger D, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Descamps D, Calvez V, Flandre P, Marcelin AG, ANRS AC11 Resistance Study Group
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1507–1512.
Raymond S, Maillard A, Amiel C, Peytavin G, Trabaud MA, Desbois D, Bellecave P, Delaugerre C, Soulie C, Marcelin AG, Descamps D, Izopet J, on behalf the ANRS AC11 Resistance Study Group
Virological failure of patients on maraviroc-based antiretroviral therapy.
The Journal of Antimicrobial Chemotherapy 2015
Loubet P, Charpentier C, Visseaux B, Borbor A, Nuta C, Adu E, Chapplain JM, Baysah M, Tattevin P, Yazdanpanah Y, Descamps D
Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1881-1884.
Charpentier C, Lee GQ, Rodriguez C, Visseaux B, Storto A, Fagard C, Molina JM, Katlama C, Yazdanpanah Y, Harrigan PR, Descamps D
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
The Journal of Antimicrobial Chemotherapy 2015, 70, 2090-2096.
Frange P, Assoumou L, Descamps D, Chéret A, Goujard C, Tran L, Gousset M, Avettand-Fenoël V, Bocket L, Fafi-Kremer S, Guinard J, Morand-Joubert L, Nicot F, Plantier JC, Rogez S, Wirden M, Rouzioux C, Meyer L, Chaix ML, French ANRS CO 6 PRIMO Cohort, the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups, French ANRS CO 6 PRIMO Cohort the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups
HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.
The Journal of Antimicrobial Chemotherapy 2015, 70, 2084–2089.
Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.
Visseaux B, Charpentier C, Ozanne A, Nizard A, Drumard S, Fagard C, Glohi D, Damond F, Brun-Vézinet F, Matheron S, Descamps D, ANRS CO5 HIV-2 Cohort
Tropism distribution among antiretroviral-naive HIV-2-infected patients.
AIDS (London, England) 2015, 29, 2209–2212.
Pain JB, Lê MP, Caseris M, Amiel C, Lassel L, Charpentier C, Desnoyer A, Farnoux C, Pialoux G, Descamps D, Peytavin G
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
Antimicrobial Agents and Chemotherapy 2015, 59, 3660–3662.
Deuzing IP, Charpentier C, Wright DW, Matheron S, Paton J, Frentz D, van de Vijver DA, Coveney PV, Descamps D, ANRS CO5 HIV-2 Cohort, Boucher CAB, Beerens N
Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.
J. Virol. 2015, 89, 833–843.
Chauveau L, Puigdomenech I, Ayinde D, Roesch F, Porrot F, Bruni D, Visseaux B, Descamps D, Schwartz O
HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells.
Retrovirology 2015, 12, 2.
Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TFR, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CAB, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HHM, van de Vijver DAMC, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JPA, Vandamme AM, Shafer RW
Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis.
PLoS medicine 2015, 12,
Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TFR, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CAB, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Kee PN, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HHM, van de Vijver DAMC, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JPA, Vandamme AM, Shafer RW
Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis.
PLoS medicine 2015, 12, e1001845.
Rodriguez C, Soulié C, Marcelin AG, Calvez V, Descamps D, Charpentier C, Flandre P, Recordon-Pinson P, Bellecave P, Pawlotsky JM, Masquelier B, ANRS AC11 Study Group
HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
PloS One 2015, 10, e0127816.
Charpentier C, Lê MP, Joly V, Visseaux B, Lariven S, Phung B, Yéni P, Yazdanpanah Y, Descamps D, Peytavin G, Landman R
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.
PloS One 2015, 10, e0134430.
Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
PloS One 2015, 10, e0134904.
Lê MP, Mandelbrot L, Descamps D, Soulié C, Ichou H, Bourgeois-Moine A, Damond F, Lariven S, Valantin MA, Landman R, Faucher P, Tubiana R, Duro D, Meier F, Legac S, Bourse P, Mortier E, Dommergues M, Calvez V, Matheron S, Peytavin G
Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
Antiviral Therapy 2015, 20, 507-513.
2014
Loubet P, Charpentier C, Visseaux B, Nuta C, Adu E, Chapplain JM, Baysah M, Walters-Doe S, Tattevin P, Peytavin G, Yazdanpanah Y, Descamps D
Short communication: Prevalence of HIV-1 transmitted drug resistance in Liberia.
AIDS research and human retroviruses 2014, 30, 863-866.
Lambert-Niclot S, Charpentier C, Storto A, Fofana D, Soulie C, Fourati S, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
The Journal of Antimicrobial Chemotherapy 2014, 69, 1086–1089.
Charpentier C, Joly V, Ghosn J, Yeni P, Raffi F, Descamps D, Morand-Joubert L
Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen.
The Journal of Antimicrobial Chemotherapy 2014, 69, 2588–2590.
Charpentier C, Choquet M, Joly V, Yeni P, Visseaux B, Caseris M, Brun-Vézinet F, Yazdanpanah Y, Peytavin G, Descamps D, Landman R
Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.
The Journal of Antimicrobial Chemotherapy 2014, 69, 2819-2825.
Soulie C, Descamps D, Grudé M, Schneider V, Trabaud MA, Morand-Joubert L, Delaugerre C, Montes B, Barin F, Ferre V, Raymond S, Jeulin H, Alloui C, Yerly S, Pallier C, Reigadas S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG, on behalf of the ANRS Resistance AC11 Group
Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.
The Journal of Antimicrobial Chemotherapy 2014
Visseaux B, Charpentier C, Rouard C, Fagard C, Glohi D, Tubiana R, Damond F, Brun-Vézinet F, Matheron S, Descamps D, French HIV-2 ANRS Cohort CO5
HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients.
AIDS (London, England) 2014, 28, 2160–2162.
Avettand-Fenoel V, Damond F, Gueudin M, Matheron S, Mélard A, Collin G, Descamps D, Chaix ML, Rouzioux C, Plantier JC, ANRS-CO5 HIV-2 and the ANRS-AC11 Quantification Working Group
New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load.
Journal of Clinical Microbiology 2014, 52, 3017–3022.
Rouet F, Kania D, Tuaillon E, Maiga A, Nouhin J, Rouzioux C, Descamps D, Plantier JC
Use of reverse transcription-PCR-based assays for quantification of HIV-1 in dried blood spots requires specific HIV-1 RNA isolation for monitoring of antiretroviral treatment efficiency.
Journal of Clinical Microbiology 2014, 52, 2740–2741.
Marcelin AG, Charpentier C, Wirden M, Descamps D, Calvez V
Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment.
Journal of the International AIDS Society 2014, 17, 19744.
2013
Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, Schneider V, Ferre V, Izopet J, Si-Mohamed A, Maillard A, Henquell C, Desbois D, Lazrek M, Signori-Schmuck A, Rogez S, Yerly S, Trabaud MA, Plantier JC, Fourati S, Houssaini A, Masquelier B, Calvez V, Flandre P, ANRS AC11 Resistance Group
A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
International Journal of Antimicrobial Agents 2013, 42, 42-47.
Charpentier C, Camacho R, Ruelle J, Kaiser R, Eberle J, Gürtler L, Pironti A, Stürmer M, Brun-Vézinet F, Descamps D, Obermeier M
HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2013, 56, 1654-1658.
Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D, ANRS 130 APOLLO Trial Study Group
Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.
The Journal of Antimicrobial Chemotherapy 2013, 68, 690-696.
Reigadas S, Marcelin AG, Houssaïni A, Yerly S, Descamps D, Plantier JC, Ruffault A, Amiel C, Trabaud MA, Flandre P, Fleury H, Masquelier B, ANRS AC11 Resistance Study Group
HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.
The Journal of Antimicrobial Chemotherapy 2013, 68, 969-972.
Lê MP, Gervais A, Le Beller C, Long K, Larrouy L, Papy E, Mal H, Descamps D, Peytavin G
Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir.
The Journal of Antimicrobial Chemotherapy 2013, 68, 1208-1209.
Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulié C, Fourati S, Visseaux B, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
The Journal of Antimicrobial Chemotherapy 2013, 68, 1237-1242.
Assoumou L, Descamps D, Yerly S, Dos Santos G, Marcelin AG, Delaugerre C, Morand-Joubert L, Ruffault A, Izopet J, Plantier JC, Pakianather S, Montes B, Chaix ML, Wirden M, Costagliola D, Masquelier B, ANRS AC11 Resistance Group
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.
The Journal of Antimicrobial Chemotherapy 2013, 68, 1400-1405.
Charpentier C, Lambert-Niclot S, Visseaux B, Morand-Joubert L, Storto A, Larrouy L, Landman R, Calvez V, Marcelin AG, Descamps D
Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010.
The Journal of Antimicrobial Chemotherapy 2013, 68, 2197-2198.
Fourati S, Visseaux B, Armenia D, Morand-Joubert L, Artese A, Charpentier C, Van Den Eede P, Costa G, Alcaro S, Wirden M, Perno CF, Ceccherini Silberstein F, Descamps D, Calvez V, Marcelin AG
Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors.
The Journal of Antimicrobial Chemotherapy 2013, 68, 2199-2204.
Descamps D, Assoumou L, Chaix ML, Chaillon A, Pakianather S, de Rougemont A, Storto A, Dos Santos G, Krivine A, Delaugerre C, Montes B, Izopet J, Charpentier C, Wirden M, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Guinard J, Tamalet C, Cottalorda J, Marcelin AG, Desbois D, Henquell C, Calvez V, Brun-Vézinet F, Masquelier B, Costagliola D, ANRS AC11 Resistance Study Group
National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.
The Journal of Antimicrobial Chemotherapy 2013, 68, 2626-2631.
Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vézinet F, Plantier JC, Descamps D
In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
AIDS (London, England) 2013, 27, 2959-2961.
Larrouy L, Vivot A, Charpentier C, Bénard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D, ANRS CO5 HIV-2 Cohort
Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
AIDS (London, England) 2013, 27, 69-80.
Visseaux B, Charpentier C, Taieb A, Damond F, Bénard A, Larrouy L, Chêne G, Brun-Vézinet F, Matheron S, Descamps D, ANRS CO5 HIV-2 Cohort
Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.
AIDS (London, England) 2013, 27, 292-295.
Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort
Transmitted drug resistance in French HIV-2-infected patients.
AIDS 2013, 27, 1671–1674.
Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P, S 130 Apollo Trial Group
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Antimicrobial Agents and Chemotherapy 2013, 57, 758-765.
Recordon-Pinson P, Raymond S, Bellecave P, Marcelin AG, Soulie C, Descamps D, Calvez V, Harrigan PR, Fleury H, Izopet J, Masquelier B, S AC11 Resistance Study Group
HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
Antimicrobial Agents and Chemotherapy 2013, 57, 930-935.
Parienti JJ, Barrail-Tran A, Duval X, Nembot G, Descamps D, Vigan M, Vrijens B, Panhard X, Taburet AM, Mentre F, Goujard C
Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.
Antimicrob Agents Chemother 2013, 57, 2265-71.
Charpentier C, Fagard C, Colin C, Katlama C, Molina JM, Jacomet C, Visseaux B, Taburet AM, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D, ANRS139 TRIO Trial study group
Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
PloS One 2013, 8, e53621.
Charpentier C, Lambert-Niclot S, Alteri C, Storto A, Flandre P, Svicher V, Perno CF, Brun-Vézinet F, Calvez V, Marcelin AG, Ceccherini-Silberstein F, Descamps D
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes.
PloS One 2013
Charpentier C, Champenois K, Gervais A, Landman R, Joly V, Le Gac S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, Yazdanpanah Y
Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients.
PloS One 2013, 8, e59205.
Zucman D, De Truchis P, Peytavin G, Descamps D, Duvivier C, Tegna L, Weiss L, Delassus JL, Benalycherif A, Landman R
Efficacy, safety, and pharmacokinetics of once-daily boosted darunavir in pretreated HIV-infected patients.
Scandinavian Journal of Infectious Diseases 2013, 45, 407-410.
2012
Soulié C, Charpentier C, Flandre P, Nino C, Carcelain G, Simon A, Katlama C, Landman R, Brun-Vézinet F, Descamps D, Calvez V, Marcelin AG
Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism.
Journal of Medical Virology 2012, 84, 1853-1856.
Savic RM, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet AM, Goujard C, Mentré F, ANRS 134–COPHAR 3 Study Group
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
Clinical Pharmacology and Therapeutics 2012, 92, 575-583.
Thiébaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, Chêne G, Collin G, Matheron S, Descamps D, Brun-Vézinet F, French ANRS HIV-2 CO5 Cohort
Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2012, 55, 1417-1425.
Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, ANRS CO 05 HIV-2 Cohort
Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
The Journal of Infectious Diseases 2012, 205, 111-120.
Marcelin AG, Charpentier C, Wirden M, Landman R, Valantin MA, Simon A, Katlama C, Yeni P, Descamps D, Aubron-Olivier C, Calvez V
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
The Journal of Antimicrobial Chemotherapy 2012, 67, 1475-1478.
Charpentier C, Larrouy L, Visseaux B, Landman R, Levittas M, Storto A, Damond F, Yazdanpanah Y, Yeni P, Brun-Vézinet F, Descamps D
Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
The Journal of Antimicrobial Chemotherapy 2012, 67, 1459-1461.
Charpentier C, Landman R, Laouénan C, Joly V, Hamet G, Damond F, Brun-Vézinet F, Mentré F, Descamps D, Yeni P
Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.
The Journal of Antimicrobial Chemotherapy 2012, 67, 2231-2235.
Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, Yeni P, Vittecoq D, Katlama C, Molina JM, Descamps D, Chêne G, Yazdanpanah Y, ANRS 139 TRIO Trial Group
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
Journal of Acquired Immune Deficiency Syndromes (1999) 2012, 59, 489-493.
Senneville E, Gaworowska D, Topolinski H, Devemy F, Nguyen S, Singer B, Beltrand E, Legout L, Caillaux M, Descamps D, Canonne JP, Yazdanpanah Y
Outcome of patients with diabetes with negative percutaneous bone biopsy performed for suspicion of osteomyelitis of the foot.
Diabet Med 2012, 29, 56-61.
Visseaux B, Charpentier C, Hurtado-Nedelec M, Storto A, Antoine R, Peytavin G, Damond F, Matheron S, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Antimicrobial Agents and Chemotherapy 2012, 56, 137-139.
Marcelin AG, Descamps D, Tamalet C, Cottalorda J, Izopet J, Delaugerre C, Morand-Joubert L, Trabaud MA, Bettinger D, Rogez S, Ruffault A, Henquell C, Signori-Schmuck A, Bouvier-Alias M, Vallet S, Masquelier B, Flandre P, Calvez V, ANRS AC11 Resistance Study group
Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Antiviral Therapy 2012, 17, 119-123.
2011
Alcaro S, Alteri C, Artese A, Ceccherini-Silberstein F, Costa G, Ortuso F, Bertoli A, Forbici F, Santoro MM, Parrotta L, Flandre P, Masquelier B, Descamps D, Calvez V, Marcelin AG, Perno CF, Sing T, Svicher V
Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
ChemMedChem 2011, 6, 2203-2213.
Masquelier B, Taieb A, Reigadas S, Marchou B, Cheneau C, Spire B, Charpentier C, Leport C, Raffi F, Chêne G, Descamps D, APROCO-COPILOTE study group
Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.
The Journal of Antimicrobial Chemotherapy 2011, 66, 1582-1589.
Raymond S, Recordon-Pinson P, Saliou A, Delobel P, Nicot F, Descamps D, Marcelin AG, Flandre P, Calvez V, Masquelier B, Izopet J, ANRS AC11 Resistance Study Group
Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism.
The Journal of Antimicrobial Chemotherapy 2011, 66, 1972-1975.
Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vézinet F, Perno CF, Descamps D, Capt A, Calvez V, Marcelin AG
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
The Journal of Antimicrobial Chemotherapy 2011, 66, 2827-2830.
Larrouy L, Charpentier C, Landman R, Capitant C, Chazallon C, Yeni P, Peytavin G, Damond F, Brun-Vezinet F, Descamps D, ANRS 127 study group
Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
AIDS (London, England) 2011, 25, 2143-2148.
Charpentier C, Lambert-Niclot S, Larrouy L, Peytavin G, Valantin MA, Landman R, Katlama C, Yeni P, Felices M, Brun-Vézinet F, Calvez V, Marcelin AG, Descamps D
Impact of adding enfuvirtide to the predictive value of the darunavir genotypic resistance score.
Journal of Acquired Immune Deficiency Syndromes (1999) 2011, 57, e15-17.
Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chêne G, Storto A, Collin G, Bénard A, Damond F, Mouscadet JF, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.
Antimicrobial Agents and Chemotherapy 2011, 55, 1293-1295.
Larrouy L, Lambert-Niclot S, Charpentier C, Fourati S, Visseaux B, Soulié C, Wirden M, Katlama C, Yeni P, Brun-Vézinet F, Calvez V, Marcelin AG, Descamps D
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.
Antimicrobial Agents and Chemotherapy 2011, 55, 1754-1757.
Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, Damond F, Descamps D, Mouscadet JF
G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
Retrovirology 2011, 8, 68.
Charpentier C, Bellecave P, Cisse M, Mamadou S, Diakite M, Peytavin G, Tchiombiano S, Teisseire P, Pizarro L, Storto A, Brun-Vézinet F, Katlama C, Calvez V, Marcelin AG, Masquelier B, Descamps D
High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger.
Antiviral Therapy 2011, 16, 429-433.
Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet JF, Campa P, Chêne G, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05)
Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
Antiviral Therapy 2011, 16, 937-940.
2010
Ghosn J, Galimand J, Meyer L, Descamps D, Vabret A, Deveau C, Yéni P, Goujard C, Rouzioux C, Chaix ML, French ANRS CO06 PRIMO Cohort
Undetectable HIV-1 RNA load with the Cobas TaqMan v1.0 in a patient diagnosed at the time of primary HIV-1 infection.
Journal of Medical Virology 2010, 82, 1816-1818.
Depatureaux A, Leoz M, De Oliveira F, Gueudin M, Damond F, Descamps D, Brun-Vézinet F, Lemée V, Simon F, Barin F, Plantier JC
[Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data].
Medecine Et Maladies Infectieuses 2010, 40, 669-676.
Descamps D, Chaix ML, Montes B, Pakianather S, Charpentier C, Storto A, Barin F, Dos Santos G, Krivine A, Delaugerre C, Izopet J, Marcelin AG, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Tamalet C, Cottalorda J, Desbois D, Calvez V, Brun-Vezinet F, Masquelier B, Costagliola D, ANRS AC11 Resistance Study Group
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.
The Journal of Antimicrobial Chemotherapy 2010, 65, 2620-2627.
Desnoyer A, Kaied FA, Descamps D, Yeni P, Descamps V, Le Beller C, Peytavin G
Deleterious pharmacokinetic interaction between bexarotene and efavirenz.
AIDS (London, England) 2010, 24, 2296-2298.
Barrail-Tran A, Yazdanpanah Y, Goldwirt L, Chêne G, Colin C, Piketty C, Bollens D, Katlama C, Descamps D, Molina JM, Fagard C, Taburet AM, ANRS 139 study group
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
AIDS (London, England) 2010, 24, 2581-2583.
Charpentier C, Roquebert B, Colin C, Taburet AM, Fagard C, Katlama C, Molina JM, Jacomet C, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D, ANRS 139 TRIO Trial study group
Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
AIDS (London, England) 2010, 24, 2651-2656.
Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chêne G, Nie T, Schinazi R, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
AIDS (London, England) 2010, 24, 2753-2755.
Depatureaux A, Charpentier C, Collin G, Leoz M, Descamps D, Vessière A, Damond F, Rousset D, Brun-Vézinet F, Plantier JC
Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.
Antimicrobial Agents and Chemotherapy 2010, 54, 4016-4019.
Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B, ANRS AC11 Resistance Study Group
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
Antimicrobial Agents and Chemotherapy 2010, 54, 3335-3340.
Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V, ANRS AC11 Resistance Study Group
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
Antimicrobial Agents and Chemotherapy 2010, 54, 72-77.
Maïga AI, Descamps D, Morand-Joubert L, Malet I, Derache A, Cisse M, Koita V, Akonde A, Diarra B, Wirden M, Tounkara A, Verlinden Y, Katlama C, Costagliola D, Masquelier B, Calvez V, Marcelin AG
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
Antimicrobial Agents and Chemotherapy 2010, 54, 728-733.
Damond F, Avettand-Fenoel V, Collin G, Roquebert B, Plantier JC, Ganon A, Sizmann D, Babiel R, Glaubitz J, Chaix ML, Brun-Vezinet F, Descamps D, Rouzioux C
Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification.
Journal of Clinical Microbiology 2010, 48, 1413-1416.
2009
Roquebert B, Damond F, Brun-Vézinet F, Descamps D
[HIV genetic diversity and its consequences].
Pathologie-Biologie 2009, 57, 142-148.
Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
The Journal of Antimicrobial Chemotherapy 2009, 63, 585-592.
Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
The Journal of Antimicrobial Chemotherapy 2009, 64, 118-125.
Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D, ANRS AC11 Resistance Group, Cohort PRIMO ANRS CO 6, FHDH ANRS CO4 Study Groups
Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.
AIDS (London, England) 2009, 23, 717-724.
Bénard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F, Autran B, Brun-Vézinet F, Chêne G, Matheron S, ANRS CO5 HIV-2 Cohort Study Group
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
AIDS (London, England) 2009, 23, 1171-1173.
Burgard M, Boufassa F, Viard JP, Garrigue I, Ruffault A, Izopet J, Vabret A, Descamps D, Colson P, Seigneurin JM, Rouzioux C, ANRS AC11 Working Group
Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients.
AIDS (London, England) 2009, 23, 2165-2171.
Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, Damond F, Brun-Vezinet F, Nisole S, Margottin-Goguet F, Pancino G, Transy C
The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection.
Journal of Virology 2009, 83, 4854-4860.
Descamps D, Chazallon C, Loveday C, Bacheler L, Goodall R, Yéni P, Cooper DA, Babiker A, Aboulker JP, Brun-Vézinet F, Nitio Trial International Coordinating Committee
Resistance and virological response analyses in a three initial treatment strategy trial: a substudy of the INITIO trial.
HIV clinical trials 2009, 10, 385-393.
Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Kräusslich HG, Hance AJ, Clavel F, ANRS 109 Study Group
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
PLoS pathogens 2009, 5, e1000345.
2008
Caron M, Makuwa M, Souquière S, Descamps D, Brun-Vézinet F, Kazanji M
Human immunodeficiency virus type 1 seroprevalence and antiretroviral drug resistance-associated mutations in miners in Gabon, central Africa.
AIDS research and human retroviruses 2008, 24, 1225-1228.
Descamps D, Assoumou L, Masquelier B, Marcelin AG, Saidi S, Tamalet C, Cottalorda J, Plantier JC, Montes B, Izopet J, Peytavin G, Yerly S, Schneider V, Delaugerre C, Ferré V, Ruffault A, Pallier C, Morand-Joubert L, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D, ANRS AC-11 Resistance Study Group
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.
The Journal of Antimicrobial Chemotherapy 2008, 62, 451-455.
Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
The Journal of Antimicrobial Chemotherapy 2008, 62, 914-920.
Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, Toledano D, Descamps D, Brun-Vezinet F, Matheron S
Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients.
AIDS (London, England) 2008, 22, 665-666.
Roquebert B, Blum L, Collin G, Damond F, Peytavin G, Leleu J, Matheron S, Chêne G, Brun-Vézinet F, Descamps D, ANRS HIV-2 Co5 Cohort
Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
AIDS (London, England) 2008, 22, 2045-2046.
Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, Alloui C, Bouvier-Alias M, Signori-Schmuck A, Montes B, Chaix ML, Amiel C, Santos GD, Ruffault A, Barin F, Peytavin G, Lavignon M, Flandre P, Calvez V
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.
Antimicrobial Agents and Chemotherapy 2008, 52, 3237-3243.
Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Bénard A, Campa P, Matheron S, Chêne G, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Antimicrobial Agents and Chemotherapy 2008, 52, 1545-1548.
2007
Duval X, Peytavin G, Breton G, Ecobichon JL, Descamps D, Thabut G, Leport C
Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination.
AIDS (London, England) 2007, 21, 106-108.
Costagliola D, Descamps D, Assoumou L, Morand-Joubert L, Marcelin AG, Brodard V, Delaugerre C, Mackiewicz V, Ruffault A, Izopet J, Plantier JC, Tamalet C, Yerly S, Saidi S, Brun-Vezinet F, Masquelier B, Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS) AC11 Resistance Study Group
Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study.
Journal of Acquired Immune Deficiency Syndromes (1999) 2007, 46, 12-18.
Damond F, Roquebert B, Bénard A, Collin G, Miceli M, Yéni P, Brun-Vezinet F, Descamps D
Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays.
Journal of Clinical Microbiology 2007, 45, 3436-3438.
Chaix ML, Desquilbet L, Descamps D, Costagliola D, Deveau C, Galimand J, Goujard C, Signori-Schmuck A, Schneider V, Tamalet C, Pellegrin I, Wirden M, Masquelier B, Brun-Vezinet F, Rouzioux C, Meyer L, French PRIMO Cohort Study Group (ANRS CO 06), French ANRS AC11 Resistance Study Group
Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
Antiviral Therapy 2007, 12, 1305-1310.
2006
Descamps D, Delaugerre C, Masquelier B, Ruffault A, Marcelin AG, Izopet J, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D
Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance.
Journal of Medical Virology 2006, 78, 153-160.
Descamps D, Damond F, Bénard A, Matheron S, Campa P, Taieb A, Yahyaoui R, Chêne G, Brun-Vézinet F
No association between GB virus C infection and disease progression in HIV-2-infected patients from the French ANRS HIV-2 cohort.
AIDS (London, England) 2006, 20, 1076-1079.
Makinson A, Masquelier B, Taieb A, Peytavin G, Waldner-Combernoux A, Collin G, Chêne G, Brun-Vézinet F, Raffi F, Le Moing V, Leport C, Descamps D
Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART.
AIDS (London, England) 2006, 20, 1327-1329.
Flandre P, Pinçon C, Aboulker JP, Brun-Vézinet F, Pialoux G, Raffi F, Descamps D
Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials.
HIV clinical trials 2006, 7, 116-124.
Launay O, Duval X, Dalban C, Descamps D, Peytavin G, Certain A, Mouajjah S, Ralaimazava P, Verdon R, Costagliola D, Clavel F, ANRS 109 VISTA Study Group
Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Antiviral Therapy 2006, 11, 889-899.
Descamps D, Ait-Khaled M, Craig C, Delarue S, Damond F, Collin G, Brun-Vézinet F
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Antiviral Therapy 2006, 11, 701-705.
2005
Masquelier B, Costagliola D, Schmuck A, Cottalorda J, Schneider V, Izopet J, Calvez V, Descamps D, Poggi C, Brun-Vézinet F, ANRS resistance sudy group
Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study.
Journal of Medical Virology 2005, 76, 441-446.
Descamps D, Joly V, Flandre P, Peytavin G, Meiffrédy V, Delarue S, Lastère S, Aboulker JP, Yeni P, Brun-Vézinet F
Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2005, 33, 99-103.
Masquelier B, Pereira E, Peytavin G, Descamps D, Reynes J, Verdon R, Fleury H, Garraffo R, Chêne G, Raffi F, Brun-Vézinet F, APROCO/COPILOTE Study Group
Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2005, 33, 75-78.
Descamps D, Chaix ML, André P, Brodard V, Cottalorda J, Deveau C, Harzic M, Ingrand D, Izopet J, Kohli E, Masquelier B, Mouajjah S, Palmer P, Pellegrin I, Plantier JC, Poggi C, Rogez S, Ruffault A, Schneider V, Signori-Schmück A, Tamalet C, Wirden M, Rouzioux C, Brun-Vezinet F, Meyer L, Costagliola D
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002.
Journal of Acquired Immune Deficiency Syndromes (1999) 2005, 38, 545-552.
Marcelin AG, Cohen-Codar I, King MS, Colson P, Guillevic E, Descamps D, Lamotte C, Schneider V, Ritter J, Segondy M, Peigue-Lafeuille H, Morand-Joubert L, Schmuck A, Ruffault A, Palmer P, Chaix ML, Mackiewicz V, Brodard V, Izopet J, Cottalorda J, Kohli E, Chauvin JP, Kempf DJ, Peytavin G, Calvez V
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
Antimicrobial Agents and Chemotherapy 2005, 49, 1720-1726.
Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S, Mammano F, Lastere S, Farfara I, Simon F, Chene G, Descamps D
Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.
Journal of Clinical Microbiology 2005, 43, 484-487.
Damond F, Collin G, Descamps D, Matheron S, Pueyo S, Taieb A, Campa P, Benard A, Chêne G, Brun-Vezinet F
Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.
Journal of Clinical Microbiology 2005, 43, 4234-4236.
Delaunay C, Brun-Vézinet F, Landman R, Collin G, Peytavin G, Trylesinski A, Flandre P, Miller M, Descamps D
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Journal of Virology 2005, 79, 9572-9578.
Duval X, Descamps D, Breton G, Darmon S, Ecobichon JL, Delarue S, Peytavin G, Leport C, Vildé JL, Brun-Vézinet F
Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia.
Antiviral Therapy 2005, 10, 197-199.
Damond F, Collin G, Matheron S, Peytavin G, Campa P, Delarue S, Taieb A, Bénard A, Chêne G, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 5 VIH-2)
Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene.
Antiviral Therapy 2005, 10, 861-865.
2004
Descamps D, Damond F, Matheron S, Collin G, Campa P, Delarue S, Pueyo S, Chêne G, Brun-Vézinet F, French ANRS HIV-2 Cohort Study Group
High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen.
Journal of Medical Virology 2004, 74, 197-201.
Flandre P, Descamps D, Joly V, Meiffredy V, Tamalet C, Izopet J, Brun-Vezinet F
A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients.
The Journal of Infectious Diseases 2004, 189, 862-870.
Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouzé B, Verdon R
Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2004, 38, 1311-1316.
Flandre P, Alcais A, Descamps D, Morand-Joubert L, Joly V
Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data.
Journal of Acquired Immune Deficiency Syndromes (1999) 2004, 35, 286-292.
Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.
Antimicrobial Agents and Chemotherapy 2004, 48, 172-175.
Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.
Antimicrobial Agents and Chemotherapy 2004, 48, 172-175.
Lastere S, Dalban C, Collin G, Descamps D, Girard PM, Clavel F, Costagliola D, Brun-Vezinet F, NARVAL Trial Group (ANRS 088)
Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.
Antiviral Therapy 2004, 9, 221-227.
Masquelier B, Tamalet C, Montès B, Descamps D, Peytavin G, Bocket L, Wirden M, Izopet J, Schneider V, Ferré V, Ruffault A, Palmer P, Trylesinski A, Miller M, Brun-Vézinet F, Costagliola D, ANRS AC11 Resistance study group
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
Antiviral Therapy 2004, 9, 315-323.
Damond F, Matheron S, Peytavin G, Campa P, Taieb A, Collin G, Delaunay C, Chêne G, Brun-Vézinet F, Descamps D
Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.
Antiviral Therapy 2004, 9, 635-636.
2003
Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D, Clinical Epidemiology Group from the French Hospital Database on HIV
Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2003, 37, 1517-1526.
Apetrei C, Descamps D, Collin G, Robertson DL, Pandrea I, Groza P, Prisecariu L, Teodorescu I, Luca V, Brun-Vézinet F
HIV type 1 diversity in northeastern Romania in 200-2001 based on phylogenic analysis of pol sequences from patient failing antiretroviral therapy.
AIDS research and human retroviruses 2003, 19, 1155-1161.
Brun-Vézinet F, Descamps D, Ruffault A, Masquelier B, Calvez V, Peytavin G, Telles F, Morand-Joubert L, Meynard JL, Vray M, Costagliola D, Narval (ANRS 088) Study group
Clinically relevant interpretation of genotype for resistance to abacavir.
AIDS (London, England) 2003, 17, 1795-1802.
Chaix ML, Descamps D, Harzic M, Schneider V, Deveau C, Tamalet C, Pellegrin I, Izopet J, Ruffault A, Masquelier B, Meyer L, Rouzioux C, Brun-Vezinet F, Costagliola D
Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France.
AIDS (London, England) 2003, 17, 2635-2643.
Ravela J, Betts BJ, Brun-Vézinet F, Vandamme AM, Descamps D, van Laethem K, Smith K, Schapiro JM, Winslow DL, Reid C, Shafer RW
HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms.
Journal of Acquired Immune Deficiency Syndromes (1999) 2003, 33, 8-14.
Kousignian I, Abgrall S, Duval X, Descamps D, Matheron S, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV
Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
Journal of Acquired Immune Deficiency Syndromes (1999) 2003, 34, 50-57.
Masquelier B, Droz C, Dary M, Perronne C, Ferré V, Spire B, Descamps D, Raffi F, Brun-Vézinet F, Chêne G, APROCO/COPILOTE Study Group
R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.
Antimicrobial Agents and Chemotherapy 2003, 47, 3623-3626.
Flandre P, Descamps D, Joly V, Meiffrédy V, Tamalet C, Izopet J, Aboulker JP, Brun-Vézinet F
Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Antiviral Therapy 2003, 8, 65-72.
Matheron S, Descamps D, Boué F, Livrozet JM, Lafeuillade A, Aquilina C, Troisvallets D, Goetschel A, Brun-Vezinet F, Mamet JP, Thiaux C, CNA3007 Study Group
Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
Antiviral Therapy 2003, 8, 163-171.
Kousignian I, Abgrall S, Duval X, Descamps D, Matheron S, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV
Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
Journal of Acquired Immune Deficiency Syndromes (1999) 2003, 34, 50-57.
2002
Tattevin P, Crémieux AC, Descamps D, Carbon C
Transfusion-related infectious mononucleosis.
Scandinavian Journal of Infectious Diseases 2002, 34, 777-778.
Flandre P, Raffi F, Descamps D, Calvez V, Peytavin G, Meiffredy V, Harel M, Hazebrouck S, Pialoux G, Aboulker JP, Brun Vezinet F
Final analysis of the Trilège induction-maintenance trial: results at 18 months.
AIDS (London, England) 2002, 16, 561-568.
Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM, Narval Trial Group
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.
AIDS (London, England) 2002, 16, 727-736.
Flandre P, Durier C, Descamps D, Launay O, Joly V
On the use of magnitude of reduction in HIV-1 RNA in clinical trials: statistical analysis and potential biases.
Journal of Acquired Immune Deficiency Syndromes (1999) 2002, 30, 59-64.
Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F, NOVAVIR (ANRS 073) Study Group
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Journal of Acquired Immune Deficiency Syndromes (1999) 2002, 31, 464-471.
Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, Leport C, Peytavin G, Vilde JL
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
Antimicrobial Agents and Chemotherapy 2002, 46, 570-574.
Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P, Novavir Study Group
Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
Antimicrobial Agents and Chemotherapy 2002, 46, 1906-1913.
Damond F, Gueudin M, Pueyo S, Farfara I, Robertson DL, Descamps D, Chène G, Matheron S, Campa P, Brun-Vézinet F, Simon F
Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections.
Journal of Clinical Microbiology 2002, 40, 3654-3659.
Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, Leport C, Peytavin G, Vilde JL
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
Antimicrobial Agents and Chemotherapy 2002, 46, 570-574.
Flandre P, Peytavin G, Meiffredy V, Saidi Y, Descamps D, Delagnes M, Brun-Vézinet F, Raffi F, Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team
Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
Antiviral Therapy 2002, 7, 113-121.
Joly V, Descamps D, Yeni P
NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
AIDS reviews 2002, 4, 128-139.
Calvez V, Costagliola D, Descamps D, Yvon A, Collin G, Cécile A, Delaugerre C, Damond F, Marcelin AG, Matheron S, Simon A, Valantin MA, Katlama C, Brun-Vézinet F
Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.
Antiviral Therapy 2002, 7, 211-218.
1995
Descamps D, Collin G, Loussert-Ajaka I, Saragosti S, Simon F, Brun-Vézinet F
HIV-1 group O sensitivity to antiretroviral drugs.
AIDS (London, England) 1995, 9, 977-978.
